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Abstract 
 
Avian influenza (AI) is a respiratory disease of birds resulting from infection with influenza A 
viruses. Outbreaks of the highly pathogenic form of AI (HPAI) result in the loss of millions of birds 
and remain a global threat to the poultry industry. The high mutation rate of the HPAI virus and a 
proven ability to cross the species barrier raises concerns about the pandemic potential of this zoonotic 
disease. The ongoing HPAI virus outbreaks in poultry, coupled with increasing reports of human 
cases worldwide, demonstrate the need for practical means to control its rapid spread. Poultry 
vaccination provides a means for prevention and control of AI by significantly decreasing the risk of 
viral transmission. As part of control and prevention programs against HPAI, poultry vaccines are 
commonly used in countries where HPAI viruses are endemic (i.e. parts of Asia and Africa). 
However, the currently licensed poultry vaccines against AI, which are mainly produced in 
embryonated chicken eggs, have potential drawbacks in terms of their production. The slow 
production time and requirement for at least one egg per vaccine dose make it impractical to supply 
sufficient doses for mass poultry vaccination during an outbreak. Vaccine manufacturing based on a 
microbial platform offers a promising alternative due to the speed, cost and scale associated with 
cultivation of the microorganism. Previously, process simulation of a bacterially-produced capsomere 
platform, based on the VP1 capsid protein of murine polyomavirus, has indicated that 320 million 
doses of capsomere vaccines could be produced within 2.3 days. Economic analysis has shown that 
the capsomere vaccine can be produced at a cost of less than one cent per dose, presenting a financial 
advantage over other vaccines in response to AI epidemics and pandemics. This thesis addresses some 
of the challenges associated with AI vaccine production by demonstrating the design of a novel 
modular capsomere platform and production process that allows a strain-matched vaccine to be 
delivered at a speed, cost and scale suitable for effective disease control through poultry vaccination. 
The major outcomes of this work were: (i) demonstration of the potential of structure-based modular 
capsomeres as an AI vaccine candidate; (ii) demonstration of high immunogenicity of low purity 
modular capsomeres prepared using a simpler method; and (iii) development of a simple and rapid 
non-chromatographic purification process that is economical for use in poultry vaccine production. 
This study is, to the best of my knowledge, the first to report on the development of a capsomere 
vaccine platform (designated VP1dC) that allows modularisation (a strategy for displaying target 
antigenic components of pathogens, known as modules, onto a platform base carrier) of a large 
antigenic module: a structure-based designed influenza hemagglutinin (tHA1). This modular 
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capsomere (CaptHA1) comprises five copies of modular VP1dC-tHA1 and is efficiently produced in 
a stable form using Escherichia coli. CaptHA1 demonstrates high immunogenicity and confers 
complete protection against viral challenge when administered to chickens. The simplified production 
process allows CaptHA1 to be generated without solubility tags. CaptHA1 is purified using non-
chromatographic methods, without the requirement of a protein refolding process, and retains its 
structural integrity and biological functions. The outcomes of this work contribute toward the 
development of a microbial-based modular capsomere platform for large antigen presentation. The 
platform has the potential for manufacture of vaccines for administration to poultry during AI 
epidemics and pandemics.  
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Chapter 1 
Project overview 
1.1 Background 
Avian influenza (AI) has attracted international attention in recent years. Outbreaks of AI in poultry 
are a major concern due to the serious consequences they hold for both livelihoods and international 
trade. AI is caused by infection with avian influenza viruses which are members of the influenza A 
genus. Two main forms of AI have been recognised: low pathogenic avian influenza (LPAI) and 
highly pathogenic avian influenza (HPAI). Most AI viruses demonstrate low pathogenicity. However, 
HPAI viruses can arise during viral circulation in poultry flocks as a result of antigenic drift and shift 
[1, 2]. While LPAI in poultry is typically mild, HPAI exhibits high transmission and causes an almost 
100% mortality rate [2, 3]. Whilst HPAI viruses are generally endemic in many developing countries, 
in developed countries, where they are less common, outbreaks of HPAI are increasingly being 
reported. Outbreaks of HPAI have been reported in the United States (US) in 2015 [4], Europe, 
Middle East, Africa and Asia in 2016 [5] and Myanmar in 2017 [6]. Ongoing outbreaks of AI 
worldwide, together with an increasing number of human cases with over 50% mortality for HPAI 
infections [7], highlight the need for practical measures, such as disease surveillance and poultry 
vaccination, to control its rapid spread.  
Vaccination provides a measure for controlling influenza and preventing virus spread from animals 
to humans. Poultry vaccination has been shown to increase resistance to field challenge and to reduce 
viral shedding and transmission [8]. Adequate use of vaccines in conjunction with biosecurity, 
education, culling, diagnostics and surveillance could result in effective eradication of AI during an 
outbreak. However, the global practice of AI vaccination varies from infrequent use of vaccines in 
the developed world (e.g. US and Europe), due to the uncommon occurrence of AI in these areas, to 
routine use in some developing countries in Asia, Middle East, Central America and Africa where AI 
viruses frequently circulate [9, 10].  
Two types of vaccines have been commercialised for use in poultry: inactivated virus and 
recombinant virus-vectored vaccines. Inactivated AI vaccines are the most widely used in commercial 
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poultry. These vaccines are mainly produced in embryonated chicken eggs and require at least one 
egg per vaccine dose. A production time of approximately six months is a limitation of such vaccines 
and is considerably slower than the potential global spread of AI, which could occur in a matter of 
weeks. Furthermore, a potential AI pandemic could threaten global egg supplies, leading to a shortage 
of the resources required for vaccine manufacture [11]. Inactivated vaccines also incur high 
production costs due to viral inactivation, involving heat and chemicals, and the need for strong 
adjuvants [12]. Recombinant viral vector vaccines, such as Newcastle disease virus-vectored vaccine 
and Fowlpox virus-vectored vaccine, are produced in cell cultures [13, 14] which enable shorter 
production times. It has been shown, however, that these virus-vectored vaccines may be inhibited 
by maternal antibodies if poultry are vaccinated within two weeks of hatching [15]. For virus vectors 
that can replicate in the host, the immune response to the AI portion of the vaccine can be supressed 
by AI maternal antibody. In addition, pre-existing immunity to the virus vector can block or reduce 
the subsequent immune response to the virus vector and the AI insert [16]. In addition to 
commercialised vaccines, experimental second-generation AI vaccines, such as subunit and DNA 
vaccines, have also been developed [17-20]. Lengthy production times make them unsuitable for use 
as poultry vaccines in emergency outbreaks. Moreover, high production costs associated with these 
alternative vaccines are, again, problematic for countries with low socioeconomic standing. 
The limitations associated with current licensed AI vaccines underline the need for vaccines which 
can be rapidly manufactured and involve low-cost processes in order to successfully respond to a 
potential AI pandemic. Production of vaccines using a bacteria-based system offers a promising 
alternative manufacturing process due to the speed, ease and low cost associated with recombinant 
protein production in this microorganism. The overall aim of this thesis is to develop a novel vaccine 
platform and simplified bioprocessing methods that may be useful in overcoming the limitations of 
existing vaccine manufacturing processes.  
1.1.1 Viral capsomere as a vaccine platform 
A viral capsid that mimics the overall structure of a native virion, but lacks the genetic material 
required for replication, is termed a virus-like particle (VLP). VLPs are safe and effective vaccine 
candidates. Commercially licensed VLP vaccines comprised of unmodified capsid proteins are 
available for human use against hepatitis B virus (HBV), human papillomavirus (HPV) and hepatitis 
 3 
 
E virus (HEV) [21]. VLPs and their structural subunits (capsomeres) are also under development as 
vaccine delivery platforms. Murine polyomavirus (MuPyV) VLPs and capsomeres based upon the 
major structural protein VP1 have been successfully employed for the presentation of heterologous 
antigens in vaccine production [22-24]. Heterologous expression of MuPyV VP1 in Escherichia coli 
(E. coli) results in VP1 spontaneously assembling into a capsomere composed of five VP1 monomers. 
This bacterially produced capsomere is a precursor of VLP formation which can be produced at gram-
per-litre levels [25] and purified from host proteins [26, 27]. Seventy-two copies of purified 
capsomeres can be further assembled into a VLP in vitro under defined physiochemical conditions 
[28] (Figure 1-1). However, the requirements for VLP in vitro-assembly adds additional cost to 
vaccine production [29, 30] which may limit its use in low-cost markets such as the poultry industry. 
 
Figure 1-1: Structure of murine polyomavirus VP1 protein. VP1 monomers self-assemble into a 
pentameric subunit (capsomere) in E. coli, which further assemble into a virus-like particle (VLP) in 
vitro. Structure of VP1 was taken from Protein Data Bank (http://www.rcsb.org) (PDB ID 1SD) and 
visualised using UCSF Chimera.  
Capsomeres have been shown to be less immunogenic than VLPs, presumably due to the low 
complexity of their structures relative to the more complex VLPs. However, when administered with 
adjuvants, capsomeres are capable of inducing antibody titres comparable to non-adjuvanted VLPs 
[31]. Data obtained from process simulation showed that the unit cost of production of capsomeres is 
up to 69% lower than that for VLPs. This is because of its simpler downstream process and a higher 
product yield. Using capsomeres formulated with adjuvants may, therefore, achieve protective 
immune responses and maintain low vaccine cost through elimination of the VLP assembly process.  
The potential of capsomeres as a rapid-response and low-cost platform technology for use in vaccine 
manufacturing was illustrated by a process simulation based on a conservative assumption of 50 µg 
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protein per vaccine dose [30]. Using a 10-kL fermentor, 320 million doses of modular capsomere 
vaccine could be produced within three days at a cost of less than one cent per dose. Both capital 
investment and operating cost were included in the simulation [30].  
The VP1 capsomere platform has been developed to present small peptide epitopes, such as influenza 
M2e and J8 peptide, from group A streptococcus (GAS) M-protein [24]. Small peptides incorporated 
into foreign proteins often adopt structures different to their native state [22]. Consequently, 
antibodies induced against this non-native structure would be unable to bind the native pathogen. For 
this reason, strategic design is required for peptide epitope presentation [22]. Fusion of large antigenic 
modules has several benefits over small peptide epitopes, as larger antigens generally possess more 
antigenic regions and are more likely to assume their native state [32]. Presentation of the whole 
protein module, such as the globular domain of influenza hemagglutinin (HA1), has been shown to 
increase immunogenicity due to the presence of secondary structural elements necessary for 
conformational epitope formation which are more reflective of native pathogens [33]. However, 
molecular fusion of large antigens on the capsomere platform may pose challenges. Structural 
separation between each protein domain is crucial to maintaining structural integrity and preventing 
protein aggregation [24]. Successful presentation of large antigens on the VP1 capsomere platform 
has not been shown previously. In this study, a novel VP1 capsomere platform was engineered to 
successfully present a large heterologous antigen, namely the globular domain of influenza A 
hemagglutinin (HA1).  
1.1.2 Influenza hemagglutinin (HA1) as a vaccine antigen 
Hemagglutinin (HA) is a surface glycoprotein of influenza viruses. It is responsible for receptor 
binding and facilitating virus entry into target cells [34]. Antibodies raised against HA can be 
neutralising, binding to the virus and blocking attachment to host cell receptors, thus preventing 
infection [35]. Crystallography studies have shown that HA forms homotrimers which are embedded 
in the surface of the viral envelope but part of them remains surface-exposed [36]. Each HA monomer 
consists of a globular head (HA1) and a “rod-like” stalk region (HA2), linked by a single disulfide 
bond. HA2 is highly conserved among different HA subtypes and is a potential target of universal 
vaccines. In contrast, HA1 contains the receptor binding site and the strain-specific antigenic sites of 
the HA molecule. HA1 is known to induce strong antibody-mediated immune responses [37]. In 
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particular, the vast majority of antibodies are directed against several regions of HA1 [38], suggesting 
that HA1 is a promising target for vaccines. HA1 is highly insoluble when expressed in bacteria [20]. 
Numerous studies have reported that E. coli-expressed HA1 requires purification from inclusion 
bodies, denaturing and subsequent refolding [19, 33, 39]. HA1 consists of a compact head and a long 
tail which interacts with the HA2 subunit. As the majority of antigenic epitopes are present on the 
head of HA1, it was hypothesised that removing the HA1 tail would not impair immunogenicity of 
HA1. Further to this, it was investigated if structure-based design could be employed to produce a 
suitable HA1 vaccine antigen. 
1.2 Research objectives 
This Ph.D. project aims to address the limitations in the manufacture of current AI vaccines for use 
in poultry. Using a microbial expression system, the aim is to generate a cost-effective poultry vaccine 
that is both safe and efficacious. This vaccine is designed to be produced within weeks of a new strain 
being identified. 
The main objectives of this research are: 
(i) to evaluate the potential of a structure-based designed modular capsomeres 
presenting modified HA1 as a vaccine candidate. The capsomere is based on 
the VP1 of MuPyV and the modular capsomere presenting modified HA1 
vaccine is the ‘chimeric’ molecule; 
(ii) to evaluate the immunogenicity of E. coli-produced modular capsomeres 
prepared as a partially and crudely purified form compared with highly 
purified capsomeres; 
(iii) to develop a simple process for manufacture of modular capsomeres presenting 
HA1 for application in poultry vaccination. 
The rationale behind each of these research objectives is explained in the following sections. 
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1.2.1 Structure-based design of modular capsomeres 
Previously, a VP1 modular capsomere platform lacking 28 amino acids at its N-terminus and 63 
amino acids at its C-terminus was engineered to display the M2e epitope of influenza virus [40]. This 
vaccine induced a strong immune response which further conferred complete protection against 
challenge with the homologous virus in mice [40, 41]. Despite this, the platform could not be used to 
present a large antigen such as influenza HA1. Fusion of HA1 on site N of the platform resulted in 
inclusion bodies post expression in E. coli (unpublished data). It was speculated that modularising 
full-length HA1, which has a molecular mass more than 10 times that of M2e, on the same platform 
could have disrupted the structure of the modular capsomere or caused steric hindrance between the 
capsomere platform and the HA1 insert, leading to protein misfolding [42]. Previous studies have 
shown that truncated HA1 containing the necessary elements for conformational epitope formation, 
is sufficient to stimulate protective immune responses [35, 43]. Taken together, it was hypothesised 
that rational re-design of both the capsomere platform and the HA1 antigen, based on their structures, 
may result in stable and functional modular capsomeres presenting structurally-relevant 
immunogenic regions of truncated HA1. Two main questions derived from this hypothesis were: 1) 
is a structure-based designed capsomere platform suitable for large antigen presentation; and 2) do 
antibodies generated against modular capsomeres presenting structure-based designed HA1 confer 
protection in chickens? Thus, this study aims to evaluate the potential of novel modular capsomere 
designs as vaccine candidates in vivo. 
1.2.2 Investigation of crudely purified modular capsomere components 
The main goals of animal vaccination are to improve the productivity of livestock, to improve animal 
welfare and to prevent transmission of zoonotic diseases [12]. For the poultry industry, the financial 
benefit of vaccination is the key consideration for implementing a vaccination program [44]. Lower 
production costs of poultry vaccines can be achieved if the purification steps using chromatography 
are replaced with simpler, non-chromatographic methods. Studies have demonstrated that crude 
microbial extracts increase potency and enhance protective antibody responses [45, 46]. In addition, 
highly specific immunity resulting from the synergistic effect of an optimal amount of contaminants 
in the vaccine formulation was obtained from chickens immunised with a single dose of adjuvanted 
CapM2e crudely purified by selective precipitation [47]. Nonetheless, high levels of contaminants 
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may alter immunogenicity of the modular capsomere. This section evaluated the immunogenicity of 
partially and crudely purified modular capsomeres compared with that of chromatographically 
purified capsomeres. The research question posed was: can modular capsomeres of low purity deliver 
immunogenicity equivalent to highly purified capsomeres? 
1.2.3 Development of a simple bioprocess for modular capsomere production 
As reported in section 1.2.2, the costs associated with purification processes contribute to high 
vaccine costs. To achieve a cost-effective poultry vaccine, it is advantageous to merge molecular 
strategies with bioprocessing approaches. Simple production of murine polyomavirus modular 
capsomeres and VLPs presenting a rotavirus antigen as a vaccine candidate was achieved by 
integrating synthetic biological and bioprocess engineering approaches [32, 48]. The complex process 
involved in producing highly purified vaccines often introduces more costs while compromising 
vaccine yield [30]. The existing capsomere format, as discussed in 1.2.1, was tagged with a 
Glutathione S- transferase (GST) fusion protein for expression and purification purposes. 
Nevertheless, the use of a GST tag brings disadvantages, such as poor binding between the GST tag 
and affinity chromatography media (approximately 35% of GST-VP1 protein was captured by GST-
affinity chromatography) [49], formation of insoluble aggregates upon GST tag removal and the use 
of costly chromatography media [49]. Moreover, subsequent enzyme-mediated tag removal 
introduces complexity and extra cost to the bioprocess. With the aim of developing cost-effective and 
safe influenza vaccine candidates for use in poultry, the bioprocess was simplified by using non-
tagged protein expression together with selective salting-out precipitation. This new process 
eliminated costly affinity purification and subsequent GST tag release by enzymatic cleavage 
(Chapter 5). The research questions posed were: 1) does the simplified process increase final 
capsomere yield compared with the chromatography process; and 2) do the modular capsomeres 
prepared using the simplified process retain their structural integrity and functional properties?      
1.3 Thesis organisation 
This Ph.D. thesis consists of six chapters including this introductory chapter. 
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Chapter 2 provides a literature review of key topics involved in this research. The chapter includes a 
review of a vaccine platform based on the murine polyomavirus VP1 protein, limitations of current 
vaccine technologies and influenza as a target disease. 
Chapter 3 evaluates the efficacy of structure-based designed modular capsomeres presenting HA1 as 
vaccine candidates for poultry. 
Chapter 4 evaluates the immunogenicity of low purity modular capsomeres prepared using simple 
methods. 
Chapter 5 evaluates the potential of a simple bioprocess developed for low-cost modular capsomere 
vaccine preparation. 
Chapter 6 summarises the key findings from this research and suggests future research directions. 
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Chapter 2 
Literature review 
2.1 Influenza virus 
Influenza virus is a highly contagious RNA virus of the family Orthomyxoviridae. Based upon 
antigenic differences in their nucleoprotein (NP) and matrix protein 1 (M1), these viruses are 
classified into four types: Influenza A, B, C and D [1]. Influenza B and C viruses commonly infect 
humans, although both viruses have been isolated from other mammalian species [2-4]. Influenza B 
viruses exhibit low mutation rates and low genetic diversity, which seemingly restricts their 
infectivity to epidemic proportions only. Influenza C viruses typically cause only mild disease in 
children and are not considered to be of epidemic or pandemic concern [5]. Influenza D viruses 
primarily infect cattle and are not known to cause illness in humans [6]. In contrast, most influenza 
A viruses are extremely pathogenic and are capable of infecting a broad host range, for example birds 
and numerous mammals, including humans [7]. These highly mutagenic viruses are considered to 
present a significant global threat to human and animal health. 
2.2 Influenza A virus 
2.2.1 Genome structure, envelope proteins and antigenic variation 
The roughly spherical influenza A virion is composed of an outer lipid envelope, an inner layer and 
a viral core containing the genome (Figure 2-1). The lipid envelope contains three transmembrane 
proteins, glycoproteins hemagglutinin (HA) and neuraminidase (NA), which protrude from the viral 
surface, and the matrix protein 2 ion channel (M2). The inner layer resides underneath this lipid 
envelope and contains the most abundant protein in the virion, the matrix protein 1 (M1). The viral 
core is located beneath the inner layer and contains eight single-stranded negative-sense RNA 
molecules. RNA segments 1-6 encode polymerase basic protein 2 (PB2), polymerase basic protein 1 
(PB1), polymerase acidic protein (PA), HA, nucleoprotein (NP), and NA, respectively [8]. RNA 
segment 7 encodes matrix protein 1 and 2 (M1 and M2). RNA segment 8 encodes non-structural 
protein 1 (NS1) and non-structural protein 2 (NS2; also known as nuclear export protein, NEP) [8]. 
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All RNA segments are encapsidated by multiple NP molecules and associated with PB1, PB2 and PA 
to form the viral ribonucleoproteins (vRNP) complex. PB1, PB2 and PA form an RNA-dependent 
RNA polymerase complex, which is responsible for transcription and replication of viral RNA [9].  
 
Figure 2-1: Structure of influenza A virus. The viral particle is composed of an outer lipid envelope, 
an inner layer and a viral core containing the viral genome. The genome consists of eight single-
stranded RNA molecules. RNA segments 1-6 encode polymerase basic protein 2 (PB2), polymerase 
basic protein 1 (PB1), polymerase acidic protein (PA), hemagglutinin (HA), nucleoprotein (NP), and 
neuraminidase (NA), respectively. RNA segment 7 encodes matrix protein 1 and 2 (M1 and M2). RNA 
segment 8 encodes non-structural protein (NS). The outer envelope contains HA and NA, which are 
the major surface glycoproteins of the virus, and M2, which is an integral membrane protein and 
functions as an ion channel. The inner layer contains M1, which is the most abundant protein in the 
virion. Adapted from [9]. 
The envelope glycoproteins, HA and NA, have important functional roles and are also used to 
determine virus subtype. HA is the most abundant of these envelope proteins, constituting 
approximately 80% (by mass) of the outer lipid envelope. NA accounts for a further 17% [10]. HA is 
responsible for binding to sialic acid receptors on the surface of host cells and mediating membrane 
fusion during the initial stage of infection. NA plays a major role during virus replication. It facilitates 
the release of the new viruses from infected cells by cleaving sialic acid from the HA of viral progeny 
that is attached to the host cell surface via HA-sialic acid interaction [2, 7]. Both HA and NA are 
targets of protective immune responses. To date, 18 subtypes of HA and 11 subtypes of NA have 
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been identified [11, 12]. They are highly variable in sequence, with less than 50% and 30% conserved 
amino acids of HAs and NAs, respectively, among all subtypes [11, 12].  
Influenza A viruses are constantly evolving owing to two main types of variations: antigenic drift and 
antigenic shift. Antigenic drift refers to changes in HA and/or NA surface proteins caused by the 
accumulation of point mutations (substitutions, deletions and insertions) in the HA and NA genes due 
to the inaccuracy of the RNA polymerases to insert the correct nucleotide and the lack of proofreading 
function of the RNA polymerase (Figure 2-2A). These point mutations often encode amino acid 
changes in the HA and/or NA, permitting the virus to escape neutralisation by antibodies raised 
against the previous strain [13]. Antigenic drift may or may not affect the virulence of the virus with 
the potential to cause influenza epidemics [14]. Antigenic shift is a major change in the virus, resulting 
from reassortment of viral segmented RNA when cells are co-infected with two different parent 
viruses (Figure 2-2B). Reassortment of RNA segments is an important mechanism for ensuring 
antigenic variation in influenza A viruses. It occurs randomly, allowing the new generation of viruses 
to contain novel combinations of genes. Reassortment of gene segments between different subtypes 
of influenza A viruses (for example, between avian and human viruses, or avian and other animal 
viruses) has previously led to new subtypes which have caused influenza outbreaks [15]. Indeed, the 
viruses that caused the 1957 and 1968 pandemics resulted from reassortment between avian and 
human influenza A viruses, generating new subtypes H2N2 and H3N2 [16, 17]. The recent influenza 
A (H1N1) 2009 pandemic virus also resulted from the reassortment of several viruses, including 
swine and avian-like swine viruses [15, 18]. 
 
 
 16 
 
 
Figure 2-2: Antigenic drift and antigenic shift of influenza A virus. (A) Antigenic drift results in 
the production of a new HA or NA resulting from point mutations in existing HA or NA genes of the 
influenza virus. (B) Antigenic shift is the reassortment of genes from genetically distinct viruses 
during co-infection of the same host, resulting in a new subtype which is a mix of the parental viruses’ 
surface antigens. Adapted from https://courses.lumenlearning.com/microbiology/chapter/virulence-
factors-of-bacterial-and-viral-pathogens/. 
2.2.2 Influenza A virus life cycle 
Like all viruses, replication of the influenza A virus relies upon the use of host cellular machinery. 
The life cycle of the virus involves several distinct stages, including virus attachment and entry into 
host cells, replication of the viral genome and the subsequent budding of newly produced viral 
particles [10, 19] (Figure 2-3). The initial attachment of virions to host cells is mediated through the 
binding of HA to sialic residues on the host cell surface [20]. Upon binding, the virus enters the cell 
by receptor-mediated endocytosis, a process by which the cell membrane invaginates and engulfs the 
virus forming a vesicle known as the endosome [20]. The endosome harbours an acidic environment 
(pH 5-6) which induces a conformational change within the HA proteins [21]. This results in fusion 
of the viral and endosomal membranes. The low pH of the endosome mediates the opening of the M2 
ion channels, enabling acidification of the virion itself [22]. This, in turn, releases the vRNP complex 
from the M1 matrix protein, permitting their entry into the host cell cytoplasm and their migration to 
the nucleus where transcription and replication occurs [23]. Newly synthesised viral proteins and 
genetic material are produced in the nucleus and then transported to the host cell membrane where 
the assembly of new viral particles takes place [23]. HA, NA and M2 localise at the site of budding 
on the surface of the host cell membrane, while M1 assembles just beneath it. The vRNP complex is 
packaged into the virions on the inner surface of the cell membrane. Packaged virions then undergo 
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a budding process by which HA and NA are incorporated into the host membrane. In the final stage 
of the process, NA cleaves sialic acid residues from the HA glycoproteins in the new viral particles, 
allowing their release from the host cell membrane [24]. 
 
 
Figure 2-3: Influenza virus replication cycle. The virus enters a host cell by endocytosis after 
attachment of HA to the host receptor. The acidic environment within the endosome allows uncoating 
of the virus particle. Viral RNA leaves the endosome and enters the cell nucleus where transcription 
takes place. The viral proteins are translated in the cytoplasm. The viral proteins and viral RNA 
translocate to the inner surface of the host cell membrane where the new virion’s components are 
assembled. This is followed by budding of assembled parts from the host, taking with them part of the 
host cell membrane containing the internal viral proteins. Adapted from 
http://www.vetsoft.com.eg/article/ArticleData.aspx?ID=264. 
2.3 Avian influenza  
Avian influenza (AI), also known as avian flu, bird flu or fowl plague, is a respiratory disease of birds 
caused by influenza A viruses [25]. AI viruses are classified as either highly pathogenic avian 
influenza (HPAI) or low pathogenic avian influenza (LPAI) based on their molecular characteristics 
and the ability to cause severe disease in inoculated young chickens [26]. HPAI viruses have an 
intravenous pathogenicity index (IVPI) in 6-week-old chickens greater than 1.2 or cause at least 75% 
mortality in 4- to 8-week old chickens infected intravenously [27, 28]. Poultry infected with LPAI 
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viruses typically show only mild symptoms which may often go unnoticed [29]. In contrast, HPAI 
viruses cause severe infections that affect multiple internal organs and result in almost 100% 
mortality, generally within 48 hours of infection [29, 30]. HPAI viruses are caused mainly by the H5 
and H7 subtypes of influenza A virus [31]. Although the majority of AI viruses are of low 
pathogenicity, HPAI viruses can arise from LPAI viruses during circulation in poultry flocks due to 
their mutation-prone nature. A key determinant of AI virus pathogenicity is the HA glycoprotein [32]. 
HA is synthesised as a precursor molecule (HA0) which is cleaved into subunits, HA1 and HA2, by 
host proteases [33]. This cleavage is required for viral infectivity [34]. The HA0 of LPAI viruses is 
cleaved at a conserved arginine residue by trypsin-like proteases [35]. Replication of these viruses 
can only occur where such enzymes are present, i.e. respiratory and intestinal tracts [8]. In contrast, 
the HA0 of HPAI viruses have multiple basic amino acids within their cleavage sites, which permit 
cleavage by ubiquitous intracellular proteases. Therefore, HPAI viruses are able to replicate in 
extrapulmonary sites throughout the body, causing fatal systemic infections [8, 35].  
The binding of HA glycoproteins present on the surface of influenza virus is primarily influenced by 
the type of linkage that exists between sialic acid and galactose molecules present on host cells. 
Human influenza viruses preferentially bind to sialic acids that are linked to galactose with α-2,6 
linkages [36], i.e. those that are present in the human respiratory tract. Most avian influenza viruses 
preferentially bind to sialic acids with α-2,3 linkages to galactose, i.e. those present in birds [36]. For 
this reason, avian influenza viruses are largely confined to infecting birds. Swine influenza viruses, 
however, recognise both α-2,6 and α-2,3 linkages [36]. The presence of α-2,6 and α-2,3 linkages in 
the pig trachea explains why swine are believed to play a role in the adaptation of avian viruses to 
human viruses, acting as mixing vessels where intra-subtype reassortment events could occur which 
generate new pathogenic viruses [37].  
2.3.1 Ecology of avian influenza 
The ecological cycle of AI viruses can be divided into two cycles, a natural avian influenza cycle and 
an animal and human influenza cycle (Figure 2-4). In the natural cycle, wild birds, such as shorebirds 
and waterfowls, are considered the natural hosts for diverse populations of AI viruses [38]. AI viruses 
circulating in these hosts serve as parent strains for HPAI and LPAI H5 and H7 subtypes [39]. 
Infections with influenza A viruses in these birds are mostly asymptomatic and are restricted to the 
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gastrointestinal and/or the respiratory tract of the infected birds [13]. This may be due to these sites 
offering the optimal temperature and pH for replication of the HPAI viruses [40]. AI viruses are 
spread through faecal contamination of water habitats [13, 41] and can be transmitted to domestic 
birds via contamination of water on farms along the flyways of migratory birds [13] or as a result of 
domestic birds intermingling with backyard poultry [25]. However, contact between wild birds and 
farmed poultry is unlikely as wild birds have little opportunity to enter fully enclosed poultry houses 
[41]. Transmission of AI viruses to humans possibly occurs through direct contact with infected birds 
[25], the transfer of viruses via contaminated clothing or through the transportation of susceptible 
birds [41]. Inter-species transmission of AI viruses to non-poultry hosts can also occur via direct 
contact with swine which are susceptible to both avian and human influenza viruses, as previously 
described [42].  
 
Figure 2-4: The ecology of avian influenza viruses. Avian influenza viruses are transmitted from 
their natural hosts to domestic birds. AI viruses can also be transmitted to humans directly via 
domestic birds or swine, which are susceptible to both avian and human influenza viruses. Adapted 
from [43]. 
2.3.2 Avian influenza outbreaks in poultry  
Avian influenza was first described as “fowl plague” in 1878 by Perroncito in Italy [44], but the virus 
was not isolated until 1959 when the first outbreak of HPAI H5 subtype occurred in Scotland [45]. 
Prior to 1997, the H5N1 strain of AI viruses is considered to have begun circulating in poultry 
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populations throughout parts of Asia [13]. Similar to other AI viruses of the H5 and H7 subtypes, the 
H5N1 virus initially caused only mild disease with symptoms such as ruffled feathers and reduced 
egg production, allowing the virus to evade detection [46]. In 1997, following months of circulation 
in chickens, a highly pathogenic form of the virus emerged, causing almost 100% mortality in flocks 
and resulting in the first H5N1 outbreak in Hong Kong Special Administrative Region (SAR) [47]. 
At the end of 2003, the H5N1 HPAI virus became more widespread, affecting several Asian countries 
including South Korea, Vietnam, Japan, Thailand, Cambodia, Laos, Indonesia and China [48]. This 
was the world’s largest HPAI outbreak in over four decades, affecting more than 120 million birds 
and causing large-scale consequences for both the commercial poultry industry as well as rural 
subsistence farming [46, 48]. Large-scale control efforts, including prompt culling of infected and 
exposed birds, proper disposal of carcasses and quarantine and rigorous disinfection of farms, were 
implemented which resulted in rapid control of the virus outbreak [46]. However, these massive 
control efforts did not eliminate the virus. More likely, H5N1 was merely quiescent or possibly still 
active in rural areas where deaths in small backyard flocks were likely to avoid detection. In mid-
2004, further outbreaks of H5N1 were reported in Cambodia, China, Indonesia, Vietnam and 
Malaysia, a country spared in the first outbreak [46]. These outbreaks were much smaller, affecting 
less than one million poultry. Since then, evidence strongly indicates that H5N1 is endemic in parts 
of Asia [49, 50] and AI outbreaks of H5 and H7 subtypes have been reported more frequently [51]. 
In December 2014, an HPAI outbreak occurred in the US. The US Department of Agriculture’s 
Animal and Plant Health Inspection Service reported an outbreak of HPAI H5N1, H5N2 and H5N8 
that resulted in substantial mortality in domestic poultry [52, 53]. The viruses were first detected in 
commercial flocks in Iowa and Minnesota and quickly spread to 15 states by June 2015 [52]. This 
2014-2015 outbreak is the worst US avian influenza outbreak to date, affecting more than 48 million 
domestic flocks and wild birds [54]. In addition, outbreak of HPAI H5N8 were reported in poultry 
farms in Asia and Europe in 2014 [55, 56]. Since then, outbreaks have continually been reported in 
countries throughout Europe, the Middle East and Asia [57]. The latest outbreaks of H5N1 and H5N6 
were reported in Myanmar and Philippines in 2017 [57]. Table 2-1 lists major outbreaks of HPAI H5 
and H7 subtypes occurring in the period 1959 to 2017. 
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Table 2-1: Major outbreaks of HPAI H5 and H7 subtypes since 1959. Adapted from [23, 47]. 
 
Virus subtype Year Country or continent Number of poultry affected References 
H5N1 1959 Scotland 1 small farm [45] 
 1991 England 8000 [59] 
 1997 Hong Kong 1.5 million [60] 
 2002 Hong Kong 800,000 [61] 
 2003-07 Asia, Europe and Africa 100s of millions [62] 
 2014-15 US > 48 million* [53] 
 2017 Myanmar > 20,000 [41] 
H5N2 1983-84 US 17 million [63] 
 1994 Mexico millions [64] 
 1997 Italy 8,000 [65] 
 2014-15 US > 48 million* [47] 
H5N6 2017 Philippines > 26 million [57] 
H5N8 1983 Ireland 307,000 [66] 
 2014-15 US > 48 million* [53] 
 2016 Europe and Middle East > 100,000 [56, 57] 
H7N3 1963 England 29,000 [68] 
 1992 Australia 18,000 [69] 
 1995 Pakistan > 3 million [70] 
 2002 Chile 700,000 [71] 
H7N4 1997 Australia >160,000 [72] 
H7N7 1976 Australia 58,000 [73] 
 1985 Australia 240,000 [74] 
 2003 The Netherlands > 33 million [44, 75] 
 2012 Australia 50,000 [76] 
* Total number of poultry affected by HPAI H5N1, H5N2 and H5N8 outbreaks
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2.3.3 Impact of avian influenza outbreaks 
AI outbreaks can result in catastrophic economic decline, primarily due to the direct loss of birds 
from AI or from measures designed to control the spread of the virus, i.e. the destruction and disposal 
of domestic birds [77]. This was evident in the 2003-2004 HPAI outbreaks which resulted in the death 
and destruction of more than 200 million birds worldwide, causing economic losses of over US$20 
billion [78]. Direct losses from turkeys and egg-laying hens euthanised during the 2014-2015 HPAI 
outbreak in the US are estimated to be nearly US$1.6 billion. This estimated cost does not include 
activities such as cleaning-up and restocking [52]. Based on US animal health policies, when an AI 
virus (HPAI or LPAI) is detected in the US, elimination of the virus is required to be performed 
through culling and disposal of affected poultry and cleaning and disinfecting premises and 
equipment. This is followed by testing to demonstrate that the virus has been eliminated, which is 
required before farms can be repopulated. This process is labour-intensive and time-consuming. 
Poultry producers stand to lose a significant income, not only through the loss of birds, but also the 
loss of usable laying facilities which are out of production for several months [52]. 
As poultry farming is an intricate business with multiple upstream and downstream stakeholders, the 
losses from outbreaks affect, not only the poultry farmers themselves, but also connected businesses, 
such as feed suppliers, equipment sales, slaughterhouse services, processors, transport services and 
retailers [54]. Moreover, there are consequential effects on their employees, such as the loss of 
household income and potential job loss [54]. Consumer responses to AI outbreaks are often 
immediate and dramatic, resulting in additional economic losses through reduced demand for poultry 
products in affected countries [79]. The detection of H5N1 in either wild or domestic birds in Asia, 
Europe and Africa has resulted in sharp declines in sales, prices and consumption [80]. The effects 
have also been observed at an international level. As a consequence of the US outbreak of HPAI in 
December 2014, 56 trade partners imposed full or partial bans on shipments of US poultry meat and 
products. This resulted in a 13% decline in shipments to China, the European Union, Mexico, South 
Korea and Taiwan [81].  
2.3.4 Avian influenza in humans 
AI is a zoonotic disease with demonstrated ability to mutate and infect humans. Thus, in addition to 
the economic impact, the presence of HPAI outbreaks raises concerns about the emergence of new 
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viruses that could potentially cause influenza epidemics in humans. AI viruses rarely infect humans, 
although sporadic human infections with AI viruses (subtypes H5, H7 and H9) have been documented 
(Table 2-2) [26]. Symptoms of AI virus infections in humans vary from mild conjunctivitis and 
influenza-like illness to severe respiratory illness and multi-organ failure leading to mortality [82]. 
To date, HPAI H5N1 and H7N9 viruses have proven to be the most virulent in humans, causing 
severe illness and high mortality [82]. Transmission of avian influenza viruses to humans was 
believed to be rare due to a limited host range and the possible requirement of reassortment between 
human and avian influenza viruses [41]. However, direct transmission of avian influenza virus from 
domestic poultry to humans was indicated during an outbreak of the HPAI H5N1 virus in poultry in 
1997 in the SAR, Hong Kong [83]. This highlights the potential threat of HPAI to humans.
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Table 2-2: Laboratory-confirmed cases of human infection with avian influenza viruses. Adapted 
from [8, 84]. 
Virus 
subtype 
Year Country 
Number of 
cases (deaths) 
References 
H5N1 1997 Hong Kong 18 (6) [85] 
2003-09 
 
Azerbaijan, Bangladesh, 
Cambodia, China, Djibouti, 
Egypt, Indonesia, Iraq, Laos, 
Myanmar, Nigeria, Pakistan, 
Thailand, Turkey, Vietnam, 
Canada  
468 (282) [86] 
2010-14 China, Egypt, Indonesia, 
Vietnam, Bangladesh  
233 (125) [86] 
2015 Indonesia 145 (42) [86] 
2016-17 Egypt 13 (4) [86] 
H7N9 2013-17 China 1557 (623) [87] 
H7N7 1996 UK  1 [88] 
2003 The Netherlands 89 (1) [89] 
H7N3 2002-03 Italy 7 [90] 
2004 Canada 2 [91] 
2006 UK 1 [92] 
H7N2 2002-03 US 2 [93] 
2007 UK 4 [84] 
H9N2 1999 Hong Kong, China 7 [94] 
2003 Hong Kong 1 [95] 
H10N8 2013 China 1 [96] 
H10N7 2004 Egypt 2 [8] 
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2.4 Strategies for control and prevention of avian influenza 
Effective control of AI requires a combination of measures including biosecurity, education, 
diagnostics, surveillance and depopulation [58, 97]. Biosecurity refers to measures that reduce the 
risk of AI virus introduction and spread of infection. It represents the first and foremost means of 
prevention. Biosecurity covers inclusion biosecurity (quarantine) to keep the virus within infected 
premises and exclusion biosecurity to keep the virus out of virus-free premises and the surrounding 
environment. Biosecurity measures include cleaning and disinfecting to remove the contaminating 
virus and enforcing restrictions on the movement of poultry and poultry-associated items [98]. 
Education of all poultry- and allied-industry staff (i.e. owners, suppliers and wholesalers) is a critical 
aspect of the control of AI. Education on how AI is introduced and spread and how such events can 
be prevented, as well as raising awareness of individual behaviour and controlling fomite or aerosol 
movement of the virus, can greatly reduce the spread of AI viruses [99]. Accurate and rapid diagnosis 
of AI is a prerequisite to early and successful control. The speed at which AI is controlled is greatly 
dependent upon how quickly the first case is detected, the existing biosecurity and how quickly 
control strategies are implemented. Surveillance is crucial for ongoing evaluation of the success of 
control strategies and for use in decision making to certify an AI-free area, or during an AI outbreak 
to determine the area of infection for quarantine purposes [100]. During HPAI outbreaks, 
depopulation or stamping-out policies of euthanising infected and at-risk flocks has been a common 
and effective control measure in countries where the virus has been newly introduced. However, this 
control strategy usually comes at a high social and economic cost and is not the desired method from 
a disease control and animal welfare perspective [101, 102]. The implementation and maintenance of 
high standard control measures at the working farm level (industrial, semi-industrial and backyard 
farms) can prevent infection penetration and perpetuation in farm systems [101]. However, 
implementation of control strategies differs between small backyard bird flocks and industrially 
raised poultry and contraventions in the biosecurity system may occur [101]. This indicates the need 
to establish additional control tools for AI. 
Vaccination represents an additional level of defense against AI. It can be a powerful tool for 
controlling AI when used in conjunction with other control methods. The scientific basis for using a 
vaccination strategy is the induction of protective immunity in the target population. An effective 
vaccination program would raise the level of protective immunity in poultry flocks. Poultry 
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vaccination has been shown to increase the resistance to influenza infection in the field, reduce viral 
shedding levels (in terms of amount and duration) in vaccinated birds and reduce transmission [103]. 
The demonstrated effectiveness of poultry vaccination indicates its potential for successfully 
controlling AI. To ensure optimal outcomes, vaccination programs must be part of a wider control 
strategy that includes biosecurity and infection monitoring. Vaccination could prevent the 
introduction of AI or reduce its spread, thus minimising the negative impact on poultry production 
and reducing potential economic losses. Furthermore, poultry vaccination can also minimise the risk 
of human exposure to AI viruses, reducing the number of humans affected by the virus and reducing 
the likelihood of a human influenza pandemic. 
Poultry vaccines are commonly used in control and prevention programs against H5N1 HPAI, in 
countries where HPAI viruses are endemic (i.e. Bangladesh, China, India, Indonesia, Vietnam and 
Egypt) [104]. All HPAI and LPAI viruses of H5 and H7 subtypes are reportable to the World 
Organization for Animal Health (OIE) [102], often resulting in trade sanctions being imposed on the 
reporting country. In the event of an H5 and H7 LPAI outbreak, controlled use of AI vaccines may 
reduce virus shedding from vaccinated and then exposed birds and increase resistance to infection in 
vaccinated birds [29]. However, introduction of vaccines against H5 and H7 avian influenza viruses 
in commercialised poultry is likely to lead to trade restrictions and bans due to the presence of H5 or 
H7 antibodies in both the vaccinated and the naturally infected birds. The DIVA (differentiate 
infected from vaccinated animals) strategy has been designed to distinguish between vaccinated birds 
and birds infected with the native virus [105]. This is achieved through the administration of vaccines 
based on different strains (e.g. H5N3) than the current field strain (e.g. H5N1) and using a serological 
test, such as ELISA, to detect markers that can differentiate between vaccine-induced antibodies and 
antibodies against the field virus [105]. The DIVA principle has been proposed as a potential tool in 
assuring the safe practice of moving poultry and poultry products even when vaccination is used for 
the control of AI.  
2.5 AI vaccines for poultry application: manufacture and limitations 
Vaccine have been developed using various technologies in order to provide protection from LPAI 
and HPAI viral infections, with experimental studies demonstrating their protective efficacy in 
poultry [100]. Transgenic yeast vaccines [106] and DNA-based vaccines [107] are novel approaches 
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which have demonstrated protection, however, only two types of vaccines (inactivated vaccines and 
viral vector vaccines) are currently available for commercial use [102].  
2.5.1 Inactivated whole virus vaccines 
The majority of currently licensed AI vaccines are prepared by conventional means. This involves 
virus propagation in 9 to 11-day-old embryonated chicken eggs from specific pathogen-free (SPF) 
flocks. The infected allantoic fluids containing culture-derived virions are then harvested, chemically 
inactivated (using formalin, -propiolactone or binary ethylenimine) and subsequently formulated 
with mineral oil emulsion [108].  
Inactivated vaccines were previously prepared using strains of LPAI viruses isolated from outbreaks 
in poultry or from surveillance in wild or domestic birds [109]. These conventionally inactivated 
vaccines, aimed at H5, H7 and H9 subtypes, are commercially available and licensed for use in several 
countries around the world [110]. Despite this, the manufacture of influenza vaccines remains a 
challenge owing to the antigenic variation typical of the influenza virus which causes mismatching 
between vaccine and field strains [111]. Reverse genetics technology represents a substantial 
improvement in generating inactivated vaccines. This technology enables the modification of a HPAI 
virus to genetically match a LPAI field virus by altering the HA0 cleavage site of the HPAI virus to 
that of the LPAI virus. Modified HA and NA genes are inserted in a vaccine virus backbone. The six 
internal genes that encode for virus internal proteins can be derived from an existing influenza A virus 
vaccine strain that is known to produce high titre in eggs. This allows the production of a vaccine 
seed strain that genetically matches a circulating virus but is safe and has a high growth rate in eggs. 
For example, this technology is used to generate low pathogenicity H9N2/PR8 reassortant viruses 
that derive their HA and NA genes from an epidemic strain (Korean-isolated H9N2 viruses) and six 
internal genes from the A/Puerto Rico/8/34 egg-adapted, high-growth donor strain (PR8). These 
reassortant viruses have a higher growth rate than the parental viruses [112]. However, the higher 
growth rate may not be observed in all cases reported and not only the six internal genes but also the 
HA genes are determinants of growth rate in eggs [113]. 
Despite their efficacy, egg-based vaccines have limitations relating to production time and egg 
supply. Egg-based vaccine production requires one to two eggs per vaccine dose and it takes 
approximately six months to manufacture and distribute the vaccine. This is a significant limitation 
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since the global spread of the AI virus can occur within one month [114, 115]. Moreover, AI outbreaks 
causing high mortality in poultry flocks can lead to a drastically limited egg supply and impose 
substantial limitations on vaccine manufacture during an emergency event, such as an influenza 
pandemic [116]. In addition, maternal immunity, conferred via egg yolk to the embryo, can interfere 
with the immune response generated by these vaccines [117]. 
2.5.2 Live viral vector vaccines 
Live vector virus is an alternative strategy for creating AI vaccines. Specific genes from avian 
influenza viruses, namely those which encode proteins that generate a protective immune response 
such as the HA and NA genes, are inserted into a live virus vaccine vector. This results in expression 
of the HA and NA proteins in the vaccinated chickens upon administration. Live viral vector vaccines 
can stimulate both humoral and cellular immune responses to both the inserted and the vector virus 
[118]. Live recombinant fowl poxvirus and Newcastle disease virus vaccines with an AI H5 gene 
inserted (rFP-AIV-H5 and rNDV-AIV-H5, respectively) have been licensed and used in several 
countries [110].  
The rFP-AIV-H5 is the most common vectored technology used in AI vaccine manufacture and has 
been licensed in the US since 1988 and is also licensed in Mexico, Guatemala, El Salvador and 
Vietnam [119]. It can be administered to one-day-old chickens by subcutaneous injection or wing 
web puncture. This strategy is compatible with the DIVA concept as this vaccine can be used to 
distinguish between vaccinated birds and naturally infected birds because the vaccinated birds do not 
develop antibodies against nucleoprotein or matrix protein [109]. However, rFP-AIV-H5 vaccine is 
not effective in chickens that have previously received a poxvirus vaccine or have been infected by a 
field strain of fowl poxvirus [119].  
The rNDV-AIV-H5 vaccine has been shown to protect against both HPAI and virulent ND viruses. 
This vaccine has been licensed and heavily used in China in recent years [120]. It has advantages 
over the rFP-AIV-H5 vaccine in that it can be administered by aerosol spray or eye drop and, thus, is 
less time-consuming and labour-intensive [109]. However, similar to inactivated vaccines, maternal 
antibodies to the NDV vector or AI virus may limit vaccine replication, resulting in a suboptimal 
protective immune response [109]. 
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2.6 Virus-like particle and capsomere as vaccine platform 
A virus-like particle (VLP) is a viral capsid that resembles a native virion but lacks genetic material, 
making it non-infectious. The natural ability of VLPs to induce strong humoral and cellular immune 
responses independent of adjuvant make them potential candidates for vaccines. Many studies have 
proven the effectiveness of VLPs as vaccine candidates and demonstrated their safety, due to their 
inability to cause disease. Commercial VLP vaccines for human use are licensed for protection against 
hepatitis B virus (HBV), human papillomavirus (HPV) and Hepatitis E virus (HEV) [121]. VLPs vary 
in their structural complexity from single protein to multi-protein capsids complete with lipid 
envelopes [122]. Less complex VLPs which lack a lipid envelope can be produced using prokaryotic 
systems, such as E. coli [123, 124]. In certain instances, viral capsid proteins have been engineered 
to limit their assembly to precursor capsomeric subunits, which can be further assembled into VLPs 
in vitro under controlled and optimal physicochemical conditions [125].  
Capsomeres present the possibility of manufacturing low-cost and low complexity vaccines. Upon 
expression in E. coli, viral capsid proteins spontaneously assemble into capsomere structures [124]. 
Studies have shown that capsomeres themselves are immunogenic and can elicit a protective immune 
response, both as a vaccine against the parental pathogen [126, 127] and as a platform to present 
heterologous antigens of unrelated pathogens [128, 129]. Capsomeres formulated with adjuvants 
induce strong immune responses comparable to those of VLPs [130, 131]. In contrast to VLP 
production which is complex and challenging, production of capsomere-based vaccines eliminates 
complex in vitro assembly processes which contribute significantly to vaccine production costs. 
2.6.1 Murine polyomavirus VP1 capsomere platform 
Murine polyomavirus (MuPyV) is a member of the Polyomaviridae family [132]. It is non-enveloped 
and contains a circular double-stranded DNA genome. The viral capsid is comprised of 360 identical 
copies of the major capsid protein (VP1) which are arranged as 72 morphological subunits 
(pentamers) to create an icosahedral capsid. The viral genome is approximately 50 nm in diameter 
and encodes three structural proteins, the major structural protein, VP1, and two minor proteins, VP2 
and VP3 [133]. VP1 is a 384 amino acid protein with a molecular weight of approximately 42 kDa 
which forms the viral capsid [133]. VP2 and VP3 are not required for viral capsid formation, nor for 
stability [134]. Expression of VP1 in E. coli results in a pentameric structure composed of five 
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identical copies of VP1. This pentameric structure is referred to as the VP1 capsomere, approximately 
8 nm in diameter and has a barrel-shaped morphology [135, 136].  
The potential of MuPyV VP1 capsomere as a platform to present foreign antigens has previously 
been demonstrated [137]. Studies have shown that 63 amino acids at the C-terminal are crucial for 
VLP assembly and, thus, removal of the C-terminal of VP1 inhibits VLP formation and restricts 
assembly to capsomeres. This modified capsomere, designated VP163 (VP1dC), serves as a 
platform for insertion of an antigenic sequence. VP1 was previously engineered to contain two 
insertion sites at surface-exposed loops, S1 and S4, at amino acids 85 and 293 of wild-type VP1 
(wtVP1), respectively (Figure 2-5A). These insertion sites are also present in VP1dC (Figure 2-5B). 
Molecular fusion of a single module of extracellular matrix protein 2 (M2e) antigen from influenza 
virus into the surface-exposed loop (S1) of VP1dC resulted in five copies of M2e per capsomere and 
yielded stable modular capsomeres post expression in E. coli [137]. These modular capsomeres were 
incapable of forming VLPs in vitro, even in the presence of Ca2+ which has been shown to drive VLP 
formation [125, 138]. A study demonstrated that immunogenicity of the M2e antigen was enhanced 
when multiple copies of the M2e antigen were modularised into a single capsomere [139]. VP1dC 
was re-designed to contain four insertion sites for multiple antigenic modules insertions. The first 28 
amino acids were removed from the N-terminus of VP1dC and then two insertion sites were 
engineered at either N- or C-termini. This resulted in a capsomere with four insertion sites, designated 
VP1NC (VP1dNdC) [139] (Figure 2-5C). Modularisation of the M2e antigen by insertion of one 
each of the M2e sequence into three different insertion sites of VP1dNdC resulted in a modular 
capsomere comprising a total of 15 M2e antigenic elements (CapM2e) [140]. Mice immunised with 
CapM2e, formulated with adjuvant, developed high antigen-specific antibody levels, which further 
conferred protection against homologous live virus infection [140]. This modified capsomere served 
as carrier platform to present small peptide antigens, which are easier to modularise than large protein 
domains and whole proteins. 
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Figure 2-5: Engineering VP1 capsomere. (A) Wild-type VP1 (wtVP1) contains surface-exposed 
loops S1 (amino acid 85) and S4 (amino acid 293) and N- and C-termini. Two insertion sites were 
engineered at loops S1 and S4 of wtVP1 for molecular fusion of unrelated antigenic modules. (B) 
VP1dC was engineered by removal of 63 amino acids from the C-terminus of wtVP1 sequence. (C) 
VP1dNdC was engineered by removal of 28 amino acids from the N-terminus of VP1dC. Two 
insertion sites were engineered at N- and C-termini of VP1dNdC. This figure was generated based 
on the information available in Middelberg et al. [137] and Wibowo et al. [139].  
VP1 Capsomere platform enables capsomere vaccine to be produced using E. coli, which is a simple, 
low-cost, and high yield expression system [141]. Furthermore, this capsomere platform has been 
developed to enable large-scale production at gram-per-litre levels in a bioreactor [142]. A study 
using process models coupled with simulations has demonstrated the potential of VP1 capsomere 
platform to deliver rapidly manufactured, low-cost vaccines. Based on a simulation, 320 million doses 
of capsomere vaccine can be produced using a 10-kL fermenter in 2.3 days at a cost of less than one 
cent per dose [143].  
2.7 Hemagglutinin as a vaccine target 
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HA and NA are major target antigens in the production of subunit vaccines against influenza as they 
induce a specific humoral immune response that provides protection against, or recovery after, 
infection [144]. Immunity induced by HA and NA varies considerably due to their functional 
differences in the replication cycle of influenza viruses [145, 146]. Antibodies against HA, generated 
either during infection or vaccination, are capable of neutralising influenza viruses and prevent virus 
entry into host cells [14]. These neutralising antibodies represent the first line of defense against 
influenza infection [147] and are the most significant in terms of protective efficacy [148]. In contrast, 
anti-NA antibodies do not prevent viral infection but act at a later stage of infection by preventing the 
release of the virus from infected cells [145]. Therefore, HA is considered as the main component of 
subunit vaccines, while NA is an additional component to broaden the immune response and enhance 
vaccine effectiveness [149].  
HA is a homotrimeric glycoprotein present in the viral spikes that protrude from the lipid envelope 
of the influenza virion. Its main function is to bind sialic acid receptors present on host cells and 
thereby to mediate virus attachment and entry [2, 150]. HA is encoded by viral RNA segment 4 [151] 
and is synthesised and assembled post-translationally as a precursor polypeptide (HA0) that is 
composed of three identical monomers. Each monomer contains two distinct domains, a distal domain 
of globular shape (a globular domain; HA1) and a proximal fibrous stem-like structure (a stalk region; 
HA2), as shown in Figure 2-6. HA1 and HA2 are linked by a single disulfide bond [1]. Cleavage of 
HA0 at a single arginine residue by host protease is essential for activation of membrane fusion and 
virus infectivity [33]. HA1 contains the globular domain of HA which is distal from the viral surface. 
It contains the conserved sialic acid-binding pocket surrounded by antigenically variable antibody- 
binding sites [33, 152]. The sialic acid binding site is the cellular receptor for the influenza virus. It 
binds to the receptor binding site at the membrane distal-tip of the HA molecule, which is composed 
of residues conserved in all subtypes of influenza virus [152]. HA2 contains a fusion peptide and the 
transmembrane domain (Figure 2-6). HA2 is more conserved than HA1. The most highly conserved 
sequence of the HA molecule is the N-terminus of HA2, where only five substitutions in the first 23 
amino acids have been observed [152]. It has been shown to induce a broad-spectrum, neutralising 
immune response against different virus strains and subtypes and has been targeted for use in broad 
cross-protection vaccines [153, 154]. However, the vast majority of neutralising antibodies are 
directed against several regions within the globular head of HA1 [155], making HA1 a promising 
candidate for subtype-specific vaccines.  
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Figure 2-6: Structural features and organisation of influenza virus hemagglutinin precursor, 
HA0. HA0 monomer contains two subunits, HA1 and HA2. HA1 globular head (blue) contains sialic 
acid binding site. HA2 (purple) contains a fusion peptide (red) and the transmembrane domain. HA0 
trimer is composed of three identical monomers. Adapted from [156]. 
There are several antigenic sites within the globular head of the HA molecule. For example, the 
globular head of influenza A PR8 (H1N1) virus, used in this study, contains four antigenic sites 
(epitopes), Sa, Sb, Ca (Ca1 and Ca2) and Cb (Figure 2-7) [157]. Antigenic site Sa is located on the 
upper part of the globular head of HA1 subunit, close to the receptor binding site of each monomer 
of the HA trimer. Site Sb occupies the back region of the globular head. Site Ca consists of two 
subsites, Ca1 and Ca2, located on opposite surfaces of the HA monomer, but they form one site in 
the interface region of two HA monomers. Site Cb is located near the bottom of the globular head 
(Figure 2-7). All of these antigenic sites are conformational and formed by polypeptide sequences 
within the HA1 sequence that are located adjacent to each other [158]. Therefore, to generate the 
immune response, it is essential that HA1 is presented in its native state. However, HA1 is commonly 
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expressed as inclusion bodies in E. coli. [159, 160]. E. coli-expressed HA1 protein has been refolded 
from inclusion bodies to take on the native conformation, as reported in several studies [161-165]. 
 
 
Figure 2-7: Antigenic sites of HA1. HA1 showing antigenic sites, Sa (orange), Sb (red), Ca1(blue), 
Ca2 (green), Cb (yellow) and sialic acid (receptor)-binding site. One monomer is shown in blue. The 
other monomers are shown in dark green. Adapted from [166, 167].  
2.8 Structure-based vaccine design strategy 
Structural vaccinology uses protein structure information obtained from structural studies and/or 
protein databases to rationally engineer antigens for vaccine production. It is increasingly applied in 
vaccine design and has shown promise in generating novel vaccine antigens that are not possible 
using conventional vaccine manufacturing methods [168]. It allows the rational design of vaccines 
using information derived from the crystal structure of protein antigenic modules, containing antibody 
binding sites in complex with a protective antibody, as the starting point [168]. Antigenic epitopes 
are identified based on the protein amino acid sequences and the secondary and tertiary structures 
[169].  
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The principle of structure-based design is built on the observation that an efficacious immune 
response does not require recognition of the entire antigenic module but specific epitopes within the 
module [170]. The contacts between antigen and neutralising antibody determine a structural epitope. 
This also identifies the substructures that must be retained to preserve key epitopes, while other 
unnecessary features can be eliminated to optimise biochemical and immunologic performance. 
Using high-resolution structural information, optimised antigens can be engineered to be more stable, 
homogeneous and efficiently produced, making immunisation more practical and affordable. For 
example, structure-based design strategies have been utilised in the design of HA-based vaccines. 
Xuan et al. [165] demonstrated that a protein fragment, HA1, containing the receptor-binding pocket 
is capable of inducing both humoral and cellular immune responses against the intact virus which 
further confers protection against a viral challenge. In addition, Bommakanti et al. [171] demonstrated 
that an immunogen comprising HA2 from the H1N1 subtype (PR/8/34) provided complete protection 
against homologous viral challenge in mice.  
Moreover, understanding the structural basis of immunogenicity and immunodominance can improve 
vaccine efficacy and broaden the range of vaccine-preventable diseases [172]. Structure-based 
methods have been employed to develop vaccines for high diversity viruses, such as human 
immunodeficiency virus (HIV-1), influenza virus and hepatitis C virus (HCV) [173]. Furthermore, 
the structure-based vaccine developed for use against serogroup B meningococcus, the first genome-
derived vaccine, was recently approved for use in Europe [170]. Therefore, structure-based methods 
may enable production of an immunogenic modular capsomere vaccine that subsequently elicits 
protective immune responses.  
2.9 Linker design for modular capsomere presenting HA1 
Modularisation of large protein modules, such as HA1, may cause a steric effect between the two 
protein domains (platform and insert) which may lead to protein misfolding and aggregation when 
produced in E. coli [174]. To ensure adequate separation between the platform and the insert, flexible 
linkers can be introduced between the two domains. Glycine (G)- and serine (S)- rich flexible linkers 
(GS linkers) are commonly used. The most widely used GS linker has the sequence of (GGGGS)n 
[175]. The length of this GS linker can be modified by adjusting the copy number (n). The GS linker 
has been shown to increase correct folding and stability in several fusion proteins [175]. For instance, 
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Huston et al. [176] demonstrated that insertion of (GGGGS)3 between the C-terminus of heavy-chain 
(VH) and the N-terminus of light-chain variable (VL) regions resulted in a single-chain antibody 
fragment (scFv), which had similar specificity and affinity to the parent antibody [176]. For modular 
proteins, such as modular VP1 capsomere presenting M2e peptides, GS linkers were introduced 
between the surface-exposed loop and the M2e sequence to allow separation of the two domains 
[137]. Another flexible linker, GSAGSAAGSGEF, was designed by Waldo et al. to detect correct 
folding of green fluorescence protein (GFP)-fusion proteins [177]. This linker performs similarly to 
(GGGGS)4 linker, but with reduced amount of homologous repeats in the DNA coding sequence. 
Thus, it is less likely to be deleted during cloning using homologous recombination techniques [177]. 
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Chapter 3  
Structural-based designed modular capsomere comprising HA1 for low-
cost poultry influenza vaccination 
The entire chapter consists of the peer-reviewed journal article published as: 
Waneesorn J, Wibowo N, Bingham J, Middelberg AP, and Lua LH. Structural-based designed 
modular capsomere comprising HA1 for low-cost poultry influenza vaccination. Vaccine, 2018. 
36(22):p. 3064-3071. Available online 25 November 2016. 
The following changes have been made to the text of this chapter: 
- Page, figure, section and subsection numbering and reference style have been changed to be 
consistent with the rest of the thesis.   
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3.1 Abstract  
Highly pathogenic avian influenza (HPAI) viruses cause a severe and lethal infection in domestic 
birds. The increasing number of HPAI outbreaks has demonstrated the lack of capabilities to control 
the rapid spread of avian influenza. Poultry vaccination has been shown to not only reduce the viral 
spread in animals but also reduce transmission of the virus to humans, preventing potential pandemic 
development. However, existing vaccine technologies cannot respond to a new virus outbreak rapidly 
and at a cost and scale that is commercially viable for poultry vaccination. Here, we developed a 
modular capsomere, a subunit of virus-like particles, as a low-cost poultry influenza vaccine. 
Modified murine polyomavirus (MuPyV) VP1 capsomere was used to present structure-based 
influenza hemagglutinin (HA1) antigen. Six constructs of modular capsomeres presenting three 
truncated versions of HA1 and two constructs of modular capsomeres presenting non-modified HA1 
have been generated. These modular capsomeres were successfully produced in stable forms using 
Escherichia coli, without the need for protein refolding. Based on ELISA results, this adjuvanted 
modular capsomere (CaptHA1-3C) induced a strong antibody response (almost 105 endpoint titre) 
when administered to chickens, similar to titres obtained in the group administered with insect cell-
derived HA1 proteins. Chickens that received adjuvanted CaptHA1-3C followed by challenge with 
HPAI virus were fully protected. The results presented here indicate that this bacterially-produced 
modular capsomere platform could potentially translate into a rapid-response and low-cost vaccine 
manufacturing technology suitable for poultry vaccination. 
3.2 Introduction 
Influenza viruses cause severe respiratory tract infections, resulting in substantial morbidity and 
mortality. The increasing number of human cases of avian influenza by H5N1 and H7N9 underlines 
the threat of a possible pandemic. H5N1 avian influenza viruses have caused more than 600 
confirmed cases with 60% fatality in humans [1]. The recent highly pathogenic avian influenza 
(HPAI) outbreak in domestic poultry and wild birds in the US in 2015, affecting more than 48 million 
birds and causing economic losses of billions of dollars due to the death and culling of poultry [2-4], 
has demonstrated the lack of sophisticated capabilities to control the rapid spread of avian influenza. 
Vaccination of poultry has been shown to not only reduce the spread of influenza in poultry but also 
reduce virus transmission into humans [5], suggesting that poultry vaccination can prevent pandemic 
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development as part of a One Health approach. Although a number of alternative influenza vaccine 
candidates have been developed [6-10], vaccine cost is still high and not suitable for poultry 
vaccination, especially in developing countries [11].  
The constraints of currently available vaccines underline the need for rapidly manufactured, safe and 
low-cost vaccines for control of avian influenza. Previous studies have demonstrated the potential of 
a platform technology based on modularised murine polyomavirus (MuPyV) capsid protein VP1 
virus-like particles (VLPs) and their pentameric subunits, termed capsomeres, to present foreign 
antigens [12]. VP1 can be produced and scaled-up to gram-per-liter levels in Escherichia coli (E. 
coli) [13], followed by purification processes [14, 15]. Studies have demonstrated that the modular 
VLPs and capsomeres induce strong immune responses against targeted antigens [12, 16]. 
Capsomeres are simpler, hence, faster and cheaper to manufacture than VLPs, and are therefore well 
suited as a platform for poultry vaccine. A process simulation, based on a conservative assumption 
of 50 µg protein per vaccine dose, demonstrated that 320 million doses of modular capsomere 
vaccines can be produced in 2.3 days, at a cost of less than one cent per dose [17]. Both capital 
investment and operating cost are included in the simulation. This technology can potentially translate 
into a rapid-response and low-cost vaccine manufacturing technology suitable for poultry 
vaccination. 
VP1 capsomere has previously been used to present small peptide epitopes, such as an influenza virus 
M2e peptide antigen [12, 18]. However, modularisation of the whole antigenic protein domain to VP1 
platform has several advantages over small peptide epitopes. Presentation of the whole protein 
domain, such as the globular head (HA1) of influenza virus hemagglutinin (HA), has been shown to 
increase immunogenicity due to the presence of secondary structural elements which are necessary 
to correctly display conformational epitopes [19] and increase the number of antigenic epitopes 
presenting on the protein domain. Modularisation of large antigen to VP1 platform may pose 
challenges. It is essential to allow structural separation between two protein domains to maintain their 
intact structure, preventing protein aggregation [20]. The design of the linker is crucial to allowing 
each protein domain to form a stable and independent domain. The flexible linker 
(GSAGSAAGSGEF) designed by Waldo et al. has been shown to maintain correct folding of GFP-
fusion proteins for rapid protein-folding assay [21]. This linker reduced the amount of homologous 
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repeats in its sequence, which could have resulted in deletions during cloning using a homologous 
recombination method [21]. 
Hemagglutinin (HA), an antigen glycoprotein found on the surface of the influenza virus, is known 
to induce a strong antibody-mediated immune response [22]. The globular domain of HA (HA1) 
contains the receptor binding sites and most of the antigenic sites of the HA molecule that are targets 
for neutralising antibodies [23-25], suggesting that HA1 is a promising vaccine target.  
In this study, we have developed a modular capsomere as a low-cost poultry influenza vaccine based 
on VP1 platform. This platform was redesigned to contain two insertion sites at the N- and C-termini, 
suitable for presenting large antigens. HA1 was redesigned based on its structure to retain necessary 
elements for conformational epitope formation. Stable, immunogenic and protective modular 
capsomeres comprising structure-based designed influenza hemagglutinin globular domain (HA1) 
was produced and purified from E. coli without the need for protein refolding.   
3.3 Materials and methods 
3.3.1 Plasmid construction   
Plasmid GST-wtVP1 (pGEXVP1) for expression of GST tagged wild-type VP1 [15] was used to 
generate plasmid VP1dC (pVP1dC), the vector backbone in this study. Sixty-three amino acids were 
removed from the C-terminus of wtVP1, resulting in the assembly-incompetent mutant VP1dC [26]. 
To allow insertion of heterologous protein module into VP1dC, two insertion sites (N and C) were 
engineered. Site N was designated at the BamHI restriction site (amino acid position 5 of wtVP1). 
Site C was generated by inserting a SnaBI restriction site at amino acid position 320 of wtVP1 by 
site-directed mutagenesis with the QuikChange II Site Directed Mutagenesis kit (Agilent Stratagene, 
CA, USA). Tobacco Etch Virus protease (TEVp) recognition site was inserted between GST and site 
N using site-directed mutagenesis. Oligos 5’- 
GGTAGCGCAGGTAGTGCAGCAGGTAGCGGTGAATTT-3’ encoding amino acids 
GSAGSAAGSGEF (GSA linker) were introduced between GST and the TEVp recognition site, and 
between the BamHI site and VP1dC sequence using QuikChange II Site Directed Mutagenesis kit. 
To generate VP1-based modular capsomeres presenting HA1 constructs, amplified fragments of full-
length HA1 [HA11-326 (HA1)] and three versions of truncated HA1 [HA132-308 (tHA1-1), HA140-277 
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(tHA1-2) and HA144-268 (tHA1-3)] from influenza A strain A/Puerto Rico/8/34 (H1N1) (PR8 H1N1) 
flanked by GSA linkers at its N- and C-termini were generated by PCR. Four constructs encoding 
modular capsomeres presenting HA1 on site N, including CapHA1-N, CaptHA1-1N, CaptHA1-2N 
and CaptHA1-3N, were generated by ligating these amplified fragments into the N-terminus of 
BamHI-linearised plasmid VP1dC by using an in vivo homologous recombination method. The same 
method was used to generate two constructs encoding modular capsomeres presenting HA1 on site 
C, including CapHA1-C and CaptHA1-1C. In contrast, constructs encoding CaptHA1-2C, and 
CaptHA1-3C were generated by ligating SnaBI- and XhoI-digested amplified fragments into SnaBI- 
and XhoI-linearised pVP1dC. DNA sequences of all constructs were confirmed by DNA sequencing 
(Australian Genome Research Facility (AGRF), Brisbane, Australia). 
3.3.2 Protein expression and purification  
Modular capsomere constructs were transformed separately into chemically competent E. coli Rosetta 
(DE3) pLysS cells (Novagen, CA, USA). GST-tagged modular capsomeres were expressed as 
previously described [15] with modification. The E. coli was induced with isopropyl--D-
thiogalactopyranoside (IPTG) at a concentration of 0.05 mM. The cultures were grown at 15 C and 
180 rpm and were harvested after 8 h of induction. All culture media (Terrific Broth (TB) medium 
and Luria-Bertani (LB) agar plates) were supplemented with 50 mg.L-1 ampicillin and 34 mg.L-1 
chloramphenicol. For TB medium, tryptone was used instead of peptone. GST-tagged modular 
capsomeres were purified by chromatographic methods as previously described [15] with 
modification. For affinity chromatography, GST-tagged modular capsomeres were eluted with E 
buffer (40 mM Tris, pH 8.0, 10 mM reduced glutathione, 300 mM NaCl, 1 mM EDTA, 5% (v/v) 
glycerol, 5 mM DTT). For GST tag removal, TEVp, which was produced recombinantly as previously 
described [27], was used at 50:1 (w/w) ratio (protein:TEVp), for 2 h at room temperature. TEVp was 
removed by size exclusion chromatography (SEC) using Superdex 200 30/100 GL column, a flow 
rate of 0.5 mL.min-1 (GE Healthcare, UK) and pre-equilibrated with Tris-NaCl buffer (40 mM Tris, 
300 mM NaCl, pH 8.0). Endotoxin was removed from protein samples by anion exchange using a 
Vivapure Q Mini H spin column (Sartorius Stedim, France) as previously described [12], except Tris-
NaCl buffer was used as the equilibration buffer. 
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3.3.3 HA1 protein preparation 
HA1 protein, strain A PR8 H1N1, was produced in High FiveTM insect cells by the Protein Expression 
Facility (The University of Queensland, Australia). 
3.3.4 Capsomere characterisation 
Qualitative analysis of protein samples was performed using standard SDS-PAGE using 10% gel [28] 
and Western blot analysis. For Western blot analysis, the proteins from SDS-PAGE gel were 
transferred onto a nitrocellulose membrane and probed with mouse anti-HA antibody followed by 
horseradish peroxidase (HRP)-conjugated goat anti-mouse antibody (Bio-Rad, CA, USA). Binding 
of antibody to the proteins was visualised via chemiluminescence with the NovexECL HRP 
chemiluminescent substrate reagent kit (Novex, CA, USA). Protein samples were analysed by SEC-
HPLC using a Superdex 200 30/100 GL column (GE Healthcare, UK), a flow rate of 0.5 mL.min-1, 
and pre-equilibrated with Tris-NaCl buffer (40 mM Tris, 300 mM NaCl, pH 8.0).  
3.3.5 Hemagglutination assay  
Hemagglutination assays were performed in a 96-well V-bottomed microtiter plate (Costar, Thermo 
Fisher Scientific, MA, USA). Protein samples (VP1dC capsomeres, CaptHA1-3C and HA1 protein) 
with starting concentration of 280 µg.mL-1, were serially 2-fold diluted in PBSA (137 mM NaCl, 2.7 
mM KCl, 10.15 mM Na2HPO4, 1.76 mM KH2PO4, 0.1 mg.mL
-1 BSA, pH 7.2). The plate was 
incubated with 1.1% washed chicken red blood cells (RBCs) (Australian SPF Services Pty. Ltd.). 
Agglutination was determined after incubation for 45 min at room temperature. The highest dilution 
of antigen that showed complete agglutination of RBCs was defined as the endpoint titre of 
hemagglutination. All samples were tested in duplicate. 
3.3.6 Immunogenicity study 
Three groups of eight Gallus gallus layer chickens (Bond Enterprises, Australia) at three weeks of 
age were immunised intramuscularly with 70 µg of total protein on experimental Days 0 and 21. 
Blood samples were collected from the wing vein before the first immunisation (Day 0), three weeks 
after the first immunisation (Day 21) and two weeks after the second immunisation (Day 35). Group 
1 was immunised with VP1dC capsomeres (negative control), Group 2 received CaptHA1-3C 
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(comprising 60% VP1dC and 40% tHA1-3C by mass), and Group 3 received insect cell-based HA1 
protein (positive control). All samples were adjuvanted with aluminium hydroxide (Alhydrogel, 
Brenntag, Germany) at a 1:1 (v/v) ratio of protein to Alhydrogel. Adjuvanted samples were prepared 
as previously described [29]. All animal experimental work was reviewed and approved by The 
University of Queensland Animal Ethics Committee (AIBN/235/14/QSF). All animals were cared for 
humanely in accordance with The University of Queensland Animal Ethics Committee guidelines. 
3.3.7 Enzyme-linked immunosorbent assay (ELISA) 
ELISA was performed in 96-well Nunc-ImmunoTM MaxiSorpTM plates as described previously [29]. 
Insect cell-derived HA1 protein was used to coat the plates. Endpoint titres were determined as the 
highest dilution of serum for which the OD was 3 standard deviations above the mean OD of blank 
wells containing insect cell-derived HA1 protein and substrate. 
3.3.8 Statistical analysis 
Statistical analysis was performed on log-transformed data using GraphPad Prism Version 6.00 
(GraphPad Software Inc., CA, USA). Comparison between multiple groups was performed with one-
way ANOVA and Tukey’s multiple comparison test. p < 0.05 was considered statistically significant. 
3.3.9 Challenge study with HPAI virus 
A construct encoding CaptHA1-3C containing HA1(45-262) from influenza virus 
A/chicken/NSW/3122-1/2012 (H7N7) (H7N7CaptHA1-3C) was cloned and prepared as described in 
section 3.3.1. Three-week-old White Leghorn chickens of either sex were randomly assigned to three 
treatment groups (6 birds per group). The three groups received either H7N7CaptHA1-3C, VP1dC 
capsomeres or no vaccine. The chickens were administered 0.5 mL of vaccine-Alhydrogel adjuvant 
by the subcutaneous route at the base of the neck (Day 0), followed by a second immunisation at Day 
21. On Day 35, the chickens were challenged with influenza virus A/chicken/NSW/3122-1/2012 
(H7N7) by the mucosal (eyes, nostrils and mouth) administration of 0.2 mL inoculum containing 106.0 
median egg infectious doses (EID50). Chickens were observed for disease and were euthanised once 
they developed moderate clinical signs including hunched posture, head tucking, drooping wings, 
lethargy and unwillingness to move on disturbance, facial swelling and redness, pallor of comb and 
wattles, fluffed feathers and diarrhea. All surviving chickens were euthanised at Day 49. Clotted 
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blood samples were taken from wing vein prior to the first immunisation (Day 0) and at 7-day 
intervals afterwards (Days 7, 21, 35 and 45). Sera were collected by centrifugation at 1000 x g for 
10-15 min and were tested using a hemagglutination-inhibition assay using homologous virus [30]. 
Tissue samples were taken from all chickens after euthanasia and were fixed in 10% formalin [31]. 
Histological sections were stained with haematoxylin and eosin stain for histopathological 
examination and by an immunohistochemical stain for detection of influenza A nucleoprotein antigen 
as previously described [32]. 
3.4 Results and discussion 
Major structural protein VP1 of murine polyomavirus has been previously modified for 
modularisation of antigenic modules of small peptide antigens or large protein antigens, either in the 
capsomere [12, 18] or VLP platform [12, 15]. Figure 3-1A illustrates the newly designed VP1 
capsomere for modularisation of large antigens. Previously, a 23-amino acid M2e peptide was 
inserted into truncated VP1 missing the first 28 amino acids and the last 63 amino acids [18]. This 
CapM2e, formulated with adjuvant, has demonstrated protective efficacy in mice [16] and was highly 
immunogenic in chickens [29]. However, this capsomere format (VP1dNdC) is not suitable for 
modularisation of large protein antigens such as HA1 because the truncated N-terminus of VP1 is 
hidden within the capsomere core. HA1 has a molecular weight 10-times higher than that of M2e. 
Modularisation of HA1 onto the truncated N-terminus of VP1 is likely to cause a steric effect between 
HA1 and VP1, resulting in modular capsomere instability [21, 33]. Retaining the native N-terminus 
of VP1 may provide flexibility between HA1 and VP1, with the native 28 amino acid residues acting 
as a linker between the carrier and module, possibly leading to the formation of a stable modular 
capsomere. Therefore, a new VP1 capsomere format comprising VP1 with an intact N-terminus and 
a truncation of the last 63 amino acids (VP1dC) is presented in this study (Figure 3-1A).  
Figure 3-1B illustrates the rational design of antigenic modules derived from HA1 of influenza A 
strain PR8 H1N1 for modularisation into the new VP1 capsomere format. HA monomer contains two 
subunits, a globular head (HA1) and a stalk region (HA2), linked by a single disulfide bond. HA1 is 
a target for neutralising antibodies as it contains the receptor binding site and most of the neutralising 
epitopes of the HA molecule. However, HA1 is highly insoluble when expressed in E. coli [10, 19]. 
E. coli-expressed HA1 proteins have been purified from inclusion bodies, denatured and refolded [7, 
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8, 10, 35]. HA1 comprises a compact head and a long tail, which interacts with the HA2 subunit [10, 
36, 37], as illustrated in Figure 3-1B.  
 
 
Figure 3-1: Structure-based designed modular capsomere. (A) VP1dC capsomere platform. VP1dC 
monomer contains two insertion sites, SN and SC, for presenting antigenic module from foreign 
antigens. VP1dC expressed in E. coli spontaneously assemble into a pentameric structure, termed 
capsomere as shown in Side-view and Top-view. (B) HA1 antigenic module. HA monomer is 
composed of a globular head (HA1, beige) and a stalk region (HA2, red). Full-length HA1 contains 
amino acid residues 1-326. Three versions of truncated HA1 include tHA1-1 comprised of amino 
acids 32 to 308, tHA1-2 comprised of amino acids 40 to 277, and tHA1-3 comprised of amino acids 
44 to 268. 
All antigenic sites of HA1 are conformational and present on the head [19, 38]. Maintaining the 
correct structure of the HA1 globular head is critical for its immunogenicity. In contrast, the HA1 tail 
contains very few antigenic sites [24, 39], thus eliminating this part of the protein may not impair 
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HA1 immunogenicity. Therefore, three truncations of HA1 globular head were designed by 
selectively removing the tail, to enhance the proteins’ solubilities in E. coli [40], while retaining the 
necessary elements for formation of conformational epitopes. Four designs of HA1, including a full-
length HA1 [HA11-326 (HA1)] and three versions of truncated HA1 [HA132-308 (tHA1-1), HA140-277 
(tHA1-2), and HA144-268 (tHA1-3)], were created. Each version of HA1 contains different secondary 
structural elements. GSA linkers (GSAGSAAGSGEF) were introduced between GST, HA1 insert 
either full length or truncations and VP1dC, to allow spatial separation between each protein domain 
to maintain their intact structure. The theoretically calculated molecular weights of HA1, tHA1-1, 
tHA1-2 and tHA1-3 are 36.6, 30.7, 27.0 and 25.5 kDa, respectively. Each version of HA1 was 
modularised into either site N or C of VP1dC at the DNA level, yielding eight modular constructs 
(Figure 3-2A). 
These modular constructs were expressed as GST-tagged proteins in E. coli strain, Rosetta (DE3) 
pLysS. The theoretically calculated molecular weights of CapHA1-N, CaptHA1-1N, CaptHA1-2N, 
and CaptHA1-3N monomer are 101.5, 96.1, 91.9 and 90.4 kDa, respectively. The theoretically 
calculated molecular weights of CapHA1-C, CaptHA1-1C, CaptHA1-2C and CaptHA1-3C monomer 
are 101.7, 96.3, 92.0 and 90.5 kDa, respectively. Figure 3-2B and 3-2C show SDS-PAGE analysis of 
the expression and solubility of the modular constructs. Expression was detected on SDS-PAGE gel 
for all modular constructs. However, the level of expression and solubility varied between constructs. 
Similar level of target protein expression was observed for CapHA1-N, CaptHA1-2N and CaptHA1-
3N. The lowest expression was detected for CaptHA1-1N (Figure 3-2B). For constructs with antigen 
modularisation on the C-terminal, high expression levels were observed for CaptHA1-2C and 
CaptHA1-3C, while a relatively lower expression level was detected for CapHA1-C. The lowest 
expression level was observed for CaptHA1-1C (Figure 3-2C). The level of target protein solubility 
appeared similar for all modular constructs and the soluble fraction was approximately 50% of total 
expressed target protein. These results suggested that modularisation of antigenic module onto either 
the N- or C-terminus of VP1dC has little effect on the target protein expression or solubility. The size 
and structure of the antigenic module does affect the expression and solubility of modular protein. 
The results suggest that modular protein expression and solubility is adversely affected either by 
increase in the molecular weight or the presence of secondary structural elements of module HA1.  
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Figure 3-2: Schematic representation of HA1 constructs and SDS-PAGE analysis of the 
expression and solubility of modular capsomeres (Cap) monomer. (A) Four designs of HA1 
antigenic modules were cloned into the N-terminus of VP1dC to generate HA1-N, tHA1-1N, tHA1-
2N and tHA1-3N. Four designs of HA1 antigenic modules were cloned into the C-terminus of VP1dC 
to generate HA1-C, tHA1-1C, tHA1-2C and tHA1-3C. (B) CapHA1-N, CaptHA1-1N, CaptHA1-2N 
and CaptHA1-3N. (C) CapHA1-C, CaptHA1-1C, CaptHA1-2C and CaptHA1-3C. Lanes: (L) 
molecular weight marker, (P) pre-induced lysate, (T) total lysate, and (S) soluble lysate. Predicted 
molecular weights of the monomer of CapHA1-N, CaptHA1-1N, CaptHA1-2N, CaptHA1-3N, 
CapHA1-1C, CaptHA1-1C, CaptHA1-2C and CaptHA1-3C are 101.5, 96.1, 91.9, 90.4, 101.7, 96.3, 
92.0 and 90.5 kDa, respectively.  
CaptHA1-1N and CaptHA1-1C were not taken through to purification due to poor expression and 
solubility. CapHA1-N, CaptHA1-2N, CaptHA1-3N, CapHA1-C, CaptHA1-2C and CaptHA1-3C 
were further purified by GST affinity chromatography, followed by removal of GST tag by TEVp 
treatment [27]. Non-tagged modular capsomeres were separated from the GST tag by SEC. Endotoxin 
was removed from the purified modular capsomeres by anion exchange chromatography. Figure 3-3 
shows SEC chromatograms for the separation of the capsomeres, GST tag and protein aggregates. 
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Protein aggregates were eluted as an excluded peak at approximately 16 min, capsomeres were eluted 
at approximately 22 to 24 min depending on molecular weight, and GST dimers were eluted at 
approximately 30 min. Figure 3-3A shows VP1dC capsomeres being eluted at approximately 24 min, 
as expected. Figure 3-3 (D-G) shows CaptHA1-3N, CapHA1-C, CaptHA1-2C, and CaptHA1-3C, 
respectively, being eluted at approximately 22 min due to their higher molecular weights. Capsomere 
peaks were not observed for CapHA1-N and CaptHA1-2N. It is likely that all modular capsomeres 
were unstable post GST removal and formed aggregates under the selected buffer condition, as shown 
in Figure 3-3B and 3-3C, respectively.  
After the purification process, high capsomere yield was obtained from CaptHA1-3C (Figure 3-3G). 
The SEC data suggested that modularisation of HA1 on the C-terminus of VP1dC leads to the 
recovery of stable capsomeres as compared to poor capsomere recovery for the N-terminal modular 
capsomere module. Based on the structure of VP1dC, it is likely that site C is more flexible than site 
N, thus allowing HA1 to form a stable domain away from VP1dC. In contrast, modularising HA1 on 
site N might disrupt structure of the capsomere or might cause a steric effect between each protein 
domain leading to protein misfolding. Therefore, CaptHA1-3C was selected for subsequent study.  
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Figure 3-3: Characterisation of modular capsomeres by size exclusion chromatography, showing 
the capsomeres separated from GST proteins and protein aggregates. (A) Size exclusion 
chromatogram of VP1dC without inserts. (B)-(G) Size exclusion chromatograms of CapHA1-N, 
CaptHA1-2N, CaptHA1-3N, CapHA1-C, CaptHA1-2C and CaptHA1-3C, respectively.  
Purified CaptHA1-3C was characterised using analytical SEC (SEC-HPLC) (Figure 3-4A), SDS-
PAGE (Figure 3-4B) and Western blot analysis (Figure 3-4C). The SEC chromatogram shows a 
capsomere peak eluted at the expected time (approximately 22 min) and the presence of a small 
amount of higher molecular weight, which can be misfolded capsomeres or the oligomer form of 
capsomeres, while protein aggregates were eluted as an excluded peak at approximately 16 min as 
expected. Theoretically calculated molecular weights of VP1dC capsomere and CaptHA1-3C are 
37.6 and 63.1 kDa, respectively, are shown in Figure 3-4B. The protein bands of correct molecular 
weight were detected. Western blot analysis with mouse anti-HA sera shows specific detection of 
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CaptHA1-3C, while neither pre-induction host proteins nor VP1dC capsomere were detected (Figure 
3-4C).  
Receptor binding properties of purified CaptHA1-3C was analysed using a hemagglutination assay 
(Figure 3-4D). Weak hemagglutination (endpoint titre of 4) was observed for VP1dC capsomere. 
Strong hemagglutination was observed for CaptHA1-3C (endpoint titre of 1024), which was higher 
than HA1 protein (endpoint titre of 128). The results suggested that, most likely, purified CaptHA1-
3C presented a structure containing sialic acid receptor-binding domains maintaining its ability to 
bind to sialic acid on the surface of red blood cells.  
 
 
Figure 3-4: Analysis of purified CaptHA1-3C. (A) Size exclusion chromatogram showing the 
capsomeres separated from protein aggregates. (B) SDS-PAGE and (C) Western blot analysis with 
HA specific antibody. Lanes: (L) molecular weight marker, (1) pre-induced lysate, (2) VP1dC and 
(3) CaptHA1-3C (tHA1-3C). (D) Hemagglutination assay of VP1dC, CaptHA1-3C and HA1 proteins. 
Two-fold serial dilutions of each protein are as indicated. The bars represent the endpoint titre of 
each protein. 
Purified and characterised CaptHA1-3C was tested for its immunogenicity in chickens. Figure 3-5 
shows the HA1 specific antibody endpoint titres of sera from chickens following two intramuscular 
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immunisations with CaptHA1-3C, VP1dC capsomere as a negative control and HA1 proteins as a 
positive control. All protein samples were adjuvanted with aluminum hydroxide (Alhydrogel). The 
ELISA result shows that CaptHA1-3C induced a mean antibody endpoint titre of almost 105 after the 
second immunisation (boost), comparable to HA1 proteins and significantly higher than VP1dC (p < 
0.0001). This result indicated that microbial-based CaptHA1-3C produce similar anti-HA1 endpoint 
titres as the insect cell-produced HA1.  
 
 
Figure 3-5: HA1-specific antibody endpoint titre induced in chickens immunised with CaptHA1-
3C, VP1dC capsomere and HA1 protein. Lines represent mean titre. Statistical analysis of antibody 
titres after 2nd immunisations (boost) is presented. **** = p < 0.0001; ns = not significant. 
CaptHA1-3C containing HA1(45-262) from influenza virus A/chicken/NSW/3122-1/2012 (H7N7) 
(H7N7CaptHA1-3C) was tested for its protective efficacy, as shown in Figure 3-6. Chickens that had 
been immunised twice, 21 days apart, were totally protected against a mucosal challenge with the 
homologous live virus compared to non-immunised or VP1dC-immunised chickens (Figure 3-6A), 
which had higher levels of morbidity, mortality and histopathological lesions (encephalitis and/or 
interstitial nephritis and/or myocarditis) (Figure 3-6B and 3-6C). Lesions were associated with viral 
nucleoprotein antigen. Four of six of the immunised chickens seroconverted by Day 35, with HI titre 
(using homologous antigen) ranging from 1:8 to 1:32. None of the unimmunised or VP1dC-
immunized chickens seroconverted against HA1. 
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Figure 3-6: Protection of chickens following immunisation and viral challenge. (A) Survival curves 
(6 chickens per group). (B) Number of sick animals during 14-day period after challenge. (C) 
Numbers of chickens in each group with (hatched bar) and without (clear bar) tissue lesions and 
antigen. 
This study demonstrates that stable modular capsomeres comprising influenza HA1 can be produced 
in E. coli, which can be used as a fast, low-cost, and high yield expression system [15] without the 
need for protein refolding. This modular capsomere induced strong antibody responses when 
administered with aluminium hydroxide to chickens and induced full protection against challenge 
with HPAI H7N7 virus. Aluminium hydroxide was chosen as an initial adjuvant allowing comparison 
with previous capsomere benchmarks; subsequent work will explore animal-relevant adjuvants. The 
results presented here indicate that this VP1 capsomere platform for bacterially produced-modular 
capsomere could potentially translate into a rapid-response and low-cost vaccine manufacturing 
technology suitable for poultry vaccination. Since the development of vaccines for veterinary use, 
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especially in agriculture sectors, has become more industrial and price sensitive [41], minimising the 
cost of vaccine manufacture could contribute to low-cost vaccines. Further study is needed to explore 
simpler methods of manufacturing poultry influenza vaccine while retaining immunogenicity and 
protective efficacy. The modular capsomere combined with other adjuvants suitable for poultry 
vaccination, such as oil emulsions [42] will be explore as well.  
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Chapter 4 
Characterisation of modular capsomeres from purification modalities 
The entire chapter consists of the journal article submitted as:  
Jarurin Waneesorn, Evelyne Deplazes, Nani Wibowo, John Bingham, Anton P.J. Middelberg, and 
Linda H.L. Lua (2017). Characterisation of modular capsomeres from purification modalities. 
Submitted to Molecular Biotechnology.  
The following changes have been made to the text of this chapter: 
- Page, figure, section and subsection numbering and reference style were changed to be 
consistent with the rest of the thesis.
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4.1 Abstract 
Economic losses resulting from highly pathogenic avian influenza outbreaks have soared into the 
billions, directly affecting poultry farmers and having a significant ripple effect on downstream 
businesses. Virus transmission is primarily animal to animal; however, increasing reports of animal 
to human transmission are raising major concerns for human health. Development of a poultry 
vaccine would not only prevent avian influenza outbreaks and associated socio-economic losses, but 
also minimise the threat of virus spread to humans. We have previously demonstrated the 
effectiveness of a modular capsomere presenting structure-based designed influenza hemagglutinin 
(CaptHA1-3C; hereafter CaptHA1) produced in Escherichia coli (E. coli) for application in poultry 
vaccination. The highly purified CaptHA1 vaccine candidate (cCaptHA1) induced complete 
protection against virus challenge in administered chickens, but the costs associated with the process 
make it impractical for low-cost markets. In this study, E. coli-produced CaptHA1 prepared as 
partially purified CaptHA1 (aCaptHA1) and crudely purified CaptHA1 (pCaptHA1) were evaluated 
for their immunogenicity, to investigate whether less pure vaccine candidates can deliver 
immunogenicity equivalent to high-purity capsomeres. All three adjuvanted capsomere preparations 
induced high antibody titers (~105 endpoint titre) with hemagglutinin inhibition (HI) activity (1024, 
2048 and 32 endpoint titres for cCaptHA1, aCaptHA1 and pCaptHA1, respectively) after two doses 
of immunisation. HI titers obtained for aCaptHA1 and pCaptHA1 suggested that immunisation with 
these vaccine formulations could induce protection similar to cCaptHA1. The data presented here 
demonstrate that a simplified purification process may be sufficient to generate an effective and low-
cost vaccine suitable for poultry vaccination. 
4.2 Introduction 
Avian influenza (AI) refers to a severe respiratory disease resulting from infection with avian 
influenza A virus. The highly pathogenic form of AI (HPAI), caused mainly by H5 and H7 subtypes, 
demonstrates high transmission and mortality rates in birds [1, 2]. The loss of millions of birds during 
recent HPAI outbreaks greatly affected poultry production, processing and downstream businesses, 
causing catastrophic economic loss on a global level [2-6]. 
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The One Health Initiative recognises the connection between the health of humans, animals and 
ecosystems and raises concerns regarding virus transmission between animals and humans [7]. 
Indeed, human infections with AI virus have been reported worldwide since 1997 [8], with the most 
recent cases reported in January 2017 [9]. The global spread of the disease highlights the potential 
pandemic spread of AI. 
While most AI viruses are considered low pathogenic viruses (LPAI), viruses circulating in domestic 
poultry can mutate from LPAI to HPAI by means of viral genome drift and shift [2]. Vaccination of 
poultry against LPAI and HPAI presents a powerful tool to prevent AI outbreaks, reduce virus 
transmission and mitigate economic loss. Nevertheless, current vaccines against avian influenza A 
and the technologies used to produce them are more focused on human use. For veterinary vaccines, 
major considerations are cost per dose and the effectiveness of a single-dose administration [10]. 
Previously, we have demonstrated the effectiveness of a modular capsomere-based vaccine produced 
in E. coli for application in poultry. The modular capsomere presenting influenza hemagglutinin 
engineering using structure-based design (CaptHA1) was produced as a stable modular capsomere 
without the need for refolding [11]. A highly purified CaptHA1 (cCaptHA1) vaccine induced 
complete protection when administered to chickens. This cCaptHA1 demonstrated promise as a 
capsomere-based vaccine against AI. Notwithstanding, the use of cCaptHA1 as a cost-effective 
poultry vaccine was hindered by the high costs associated with chromatographic purification 
methods, which contribute more than 70% of the total operating cost of vaccine production [12]. 
Moreover, the recovery of cCaptHA1 prepared in this process was relatively low. A previous study 
demonstrated that immunisation with crudely purified rotavirus-like particles containing certain 
levels of contaminants resulted in immunogenicity and protective efficacy in mice [13]. In addition, 
Wibowo et al. [14] demonstrated the high immunogenicity of precipitated capsomeres (CapM2e), 
containing soluble aggregates and E. coli protein contaminants, as vaccine candidates against 
influenza. This result suggests that soluble aggregates and other bacterial contaminants presented in 
CapM2e do not affect vaccine immunogenicity [14]. With this result, simpler selective precipitation 
methods may offer an alternative method of purification for CaptHA1. 
To simplify purification steps without diminishing vaccine immunogenicity, it is essential to 
investigate which vaccine components apart from the active component or vaccine antigen can remain 
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in the vaccine. In this study, we investigated vaccine candidates of varying purity for use in poultry. 
Three CaptHA1 preparations, highly purified (cCaptHA1) containing mainly pure capsomeres, 
partially purified CaptHA1 (aCaptHA1) containing soluble aggregates and capsomeres and crudely 
purified CaptHA1 (pCaptHA1) containing soluble aggregates, capsomeres and other E. coli protein 
contaminants, were prepared. Each preparation was evaluated for its safety and efficacious use as a 
poultry vaccine candidate. 
4.3 Materials and methods 
4.3.1 Plasmid construction and protein expression  
Plasmid for the expression of GST-tagged modular capsomere presenting HA1(44-268) from influenza 
A strain A/Puerto Rico/8/34 (H1N1) (PR8 H1N1), designated as GST-CaptHA1, was generated as 
previously reported [11]. The GST-CaptHA1 was expressed in E. coli Rosetta (DE3) pLysS 
(Novagen, CA, USA) as previously described [11].  
4.3.2 Homology modelling 
The homology model of CaptHA1 was created using Modeller v9.10 [15].The structure of the 
pentameric VP1dC was used as a template. The structure of CaptHA1 was constructed using the 
polyomavirus PDB ID 1SID [16] and influenza hemagglutinin PDB ID 1RUZ as described in Lua et 
al. 2015 [17]. 
4.3.3 Preparation of highly purified CaptHA1 (cCaptHA1) 
cCaptHA1 was prepared using GST-affinity chromatography followed by size exclusion 
chromatography (SEC) as previously described [11]. GST was removed using TEVp as previously 
described [11]. Endotoxin was removed from the protein sample by anion exchange using Vivapure 
Q Mini H spin column (Sartorius Stedim, France) as previously described [11].  
4.3.4 Preparation of partially purified CaptHA1 (aCaptHA1) 
aCaptHA1 was prepared as follows. GST-CaptHA1 was initially captured by GST-affinity 
chromatography as previously described [11]. Endotoxin was subsequently removed from the protein 
sample by anion exchange using quaternary ammonium Sepharose resin (Q Sepharose resin; GE 
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Healthcare, Sweden). GST-CaptHA1 was mixed with Q Sepharose resin at a 10:1 (w/v) ratio of 
protein to Q Sepharose resin. The mixture was slowly rotated at 4 C for 30 min, and the supernatant 
was collected after centrifugation at 500 x g, 4 C for 5 min. This step was repeated five times. The 
GST tag was cleaved from the fusion protein by enzymatic reaction using TEVp prior to the 
separation of CaptHA1 from GST by SEC as previously described [11], except both fractions 
corresponding to modular capsomere and aggregates peaks were collected. These fractions were 
pooled to obtain aCaptHA1. 
4.3.5 Preparation of crudely purified CaptHA1 (pCaptHA1) 
Cell pellets containing GST-tagged CaptHA1 were resuspended in 40 mL L-buffer (40 mM Tris, 500 
mM NaCl, 1 mM EDTA, 5% (v/v) glycerol, 5 mM DTT, pH 8.0). Cells were lysed by sonication 
(Branson Sonifier 450 ultrasonicator, Branson Ultrasonics, CT, USA) on ice at an energy output of 
60 W for four bursts of 40 seconds with at least 1 min pause between each burst. Soluble lysate was 
separated from inclusion bodies and other cellular debris by centrifugation at 25,000 x g, 4 C for 20 
min. The GST tag was removed enzymatically by TEVp as previously described [11], except L-buffer 
was used. Soluble protein was precipitated with 1.0 M Na2SO4 for 2 h at room temperature. Following 
centrifugation (22,000 x g, 4C for 15 min), the supernatant was removed and the precipitate 
resuspended with L-buffer and further centrifuged (22,000 x g, 4C for 5 min). The supernatant was 
buffer exchanged using Sephadex G-25 column (GE Healthcare, UK), a flow rate of 0.5 mL. min-1 
and pre-equilibrated with Tris-NaCl buffer (40 mM Tris, 300 mM NaCl, pH 8.0). Endotoxin was 
removed from protein sample by anion exchange using quaternary ammonium Sepharose resin (Q 
Sepharose resin; GE Healthcare, Sweden) as described in Section 4.3.4. 
4.3.6 Capsomere characterisation 
Qualitative analysis of protein samples was performed using standard SDS-PAGE using 10% gel 
[18], Western blot analysis with mouse anti-HA antibody and analytical SEC with Superdex 200 
30/100 GL column (GE Healthcare, UK), as previously described [11]. 
4.3.7 Hemagglutination assay  
Hemagglutination assay was performed as previously described [11]. 
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4.3.8 Immunisation 
Four groups of eight Gallus gallus layer chickens (Bond Enterprises, Australia) were cared for 
humanely in accordance with The University of Queensland (UQ) Animal Ethics Committee 
guidelines. All animal experimental work was reviewed and approved by The UQ Animal Ethics 
Committee (AIBN/235/14/QSF). 
All groups of chickens at three weeks of age were immunised with two doses of 70 µg of total protein 
via the intramuscular route on experimental Day 0 and Day 21. Blood samples were collected from 
the wing vein at Day 0, Day 21 and Day 35. The four groups received either VP1dC capsomeres, 
cCaptHA1, aCaptHA1 or pCaptHA1. All samples were mixed with aluminium hydroxide 
(Alhydrogel, Brenntag, Germany) at a 1:1 (v/v) ratio of protein to Alhydrogel for 1 h at room 
temperature. Protein concentrations were determined using a Coomassie (Bradford) Protein Assay 
Kit (Thermo Fisher Scientific). 
4.3.9 ELISA 
ELISA was performed to detect antibodies specific for HA1, as previously described [14].  
4.3.10 Hemagglutination inhibition assay 
Hemagglutination inhibition (HI) assay was performed according to OIE Terrestrial Manual 2016 
(Chapter 2.3.4, p. 10-11) [19]. In brief, sera were serially diluted twofold in 1 x PBS pH 7.2-7.4 from 
an initial dilution of 1:4. Sera ( 25 µL) were incubated with 4 HA units of influenza A strain A/Puerto 
Rico/8/34 (H1N1) (PR8 H1N1) virus at room temperature for 1 h. An equal volume (25 µL) of 1.1 
% chicken red blood cells was added and incubated at 4 C for 45-60 min. The HI titre was determined 
as the highest dilution of serum that inhibited hemagglutination. HI values were presented as the 
geometric mean with 95% confidence interval.  
4.4. Results and discussion 
The influenza virus hemagglutinin (HA) has a key function in virus binding and facilitation of virus 
entry into the target cells. Bacterially-produced globular head (HA1) of the HA has been shown to 
induce protective immunity in ferrets [20, 21]. The efficacy of a modular capsomere presenting 
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structure-based designed HA1 (CaptHA1) as a poultry influenza vaccine candidate was previously 
evaluated [11]. Highly purified CaptHA1 (cCaptHA1) was highly immunogenic in chickens, and 
when immunised with adjuvanted antigen, chickens were 100% protected against challenge with a 
HPAI virus strain H7N7 [11].  
CaptHA1 comprises five copies of HA1(44-268) (tHA1), each molecularly-fused to the C-terminus of 
the capsid protein VP1dC (VP1(1-320)), as illustrated in Figure 4-1. Preventing structure perturbation 
of the base module VP1dC by the inserted module and maintaining the conformational structure of 
the antigenic module tHA1 are important for eliciting immunity against the targeted pathogen. A 
GSA (GSAGSAAGSGEF) linker [22] was inserted between the base module VP1dC and antigenic 
module tHA1 to provide flexibility and prevent a steric effect between the protein domains. Structure-
based designed CaptHA1 was previously described [11] to show the modularisation of antigenic 
modules without compromising the structure integrity of the capsomere. 
 
 
Figure 4-1: Homology model of modular capsomere presenting influenza HA1(44-268) (tHA1). Five 
copies of modular VP1dC-tHA1 form a modular capsomere (CaptHA1). tHA1 is illustrated in red, 
VP1dC is shown in grey and GSA linker (at the C-terminal of VP1dC) is shown in green. The 
homology model was created using Modeller v9.10. 
The established method [11] for the production of cCaptHA1 (Figure 4-2A) yielded modular 
capsomeres displaying conformational HA1 that induced protective immunity in chickens. However, 
the recovery of modular capsomeres was relatively low using this process. To investigate the 
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possibility of simplifying the processing steps required to minimally obtain immunogenic modular 
CaptHA1 for poultry vaccination, two additional methods (Figure 4-2B and 4-2C) were used to obtain 
less pure CaptHA1 preparations. One chromatographic method was used to obtain partially purified 
CaptHA1 (aCaptHA1) containing capsomeres and soluble aggregates (Figure 4-2B). The third 
method, selective salting-out precipitation, was used to obtain crudely purified CaptHA1 (pCaptHA1) 
containing capsomeres, soluble aggregates and E. coli protein contaminants (Figure 4-2C). 
 
 
Figure 4-2: Major processing steps used to produce CaptHA1. (A) Highly purified CaptHA1 
(cCaptHA1) containing pure capsomeres. (B) Partially purified CaptHA1 (aCaptHA1) containing 
capsomeres and protein aggregates. (C) Crudely purified CaptHA1 (pCaptHA1) containing 
capsomeres, protein aggregates and host-cell proteins. 
The cCaptHA1, aCaptHA1 and pCaptHA1 were characterised using analytical SEC (Figure 4-3A), 
SDS-PAGE (Figure 4-3B) and Western blot analysis (Figure 4-3C). Figure 4-3A shows the analytical 
SEC chromatograms of all three samples obtained. The cCaptHA1 contained mainly pure 
capsomeres, aCaptHA1 contained capsomeres and soluble aggregates and pCaptHA1 contained 
capsomeres, soluble aggregates and small molecular weight contaminants. Modular CaptHA1 has a 
predicted molecular weight of 90.5 kDa and was eluted at approximately 22 min. A shoulder on the 
left of the capsomere peak was observed for cCaptHA1 and aCaptHA1. This suggests that oligomeric 
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capsomeres or misfolded capsomeres or capsomeres in different conformational states were present 
in the samples. The aCaptHA1 has significantly more soluble aggregates of capsomeres (eluted at 
approximately 16 min) compared with cCaptHA1. For pCaptHA1, only a small peak was detected at 
the elution time of modular capsomeres, but a large peak corresponding to soluble aggregates was 
observed. Low molecular weight contaminants, which are likely to be host cell proteins, were detected 
on the chromatogram (elution time at approximately 31 min) and SDS-PAGE gels (Figure 4-3B, Lane 
3). Western blot analysis (Figure 4-3C) with anti-HA mouse sera confirmed that the protein bands at 
63 kDa are monomeric VP1dC-tHA1. As observed on both SDS-PAGE gels and Western blot images, 
the amount of CaptHA1 is lower in pCaptHA1 preparations compared with aCaptHA1 and cCaptHA1 
preparations because the same protein mass of each sample was loaded onto the gel. 
 
 
Figure 4-3: Characterisation of cCaptHA1, aCaptHA1 and pCaptHA1. (A) Analytical size 
exclusion chromatograms of cCaptHA1, aCaptHA1 and pCaptHA1. Peaks corresponding to 
aggregates, capsomeres and contaminants are indicated. All three samples were analysed on SDS-
PAGE gel (B) and Western blot (C) with mouse sera containing HA antibodies. Lanes: (L) molecular 
weight marker, (1) cCaptHA1, (2) aCaptHA1 and (3) pCaptHA1. 
Hemagglutination assay was conducted with all samples to test the binding of hemagglutinin to sialic 
acid receptors. Hemagglutination titres of cCaptHA1, aCaptHA1and pCaptHA1 are indicated in 
Figure 4-4A. Strong hemagglutination with an endpoint titre of 1024 was observed for high purity 
cCaptHA1. A higher endpoint titre of 2048 was observed for aCaptHA1, while pCaptHA1 had an 
endpoint titre of 32. Weak agglutination (endpoint titre of 4) was observed for VP1dC capsomeres, 
as expected (data not shown). The results suggest that aCaptHA1 and pCaptHA1 presented 
conformational HA1 with functional sialic acid-binding domains. The lower endpoint titre obtained 
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for pCaptHA1 is possibly a result of the lower amount of CaptHA1 in the protein sample. A 
comparison of the homology models of CaptHA1 and trimeric HA suggests that a modular capsomere 
with antigenic HA1 modules resembles a native trimeric HA (Figure 4-4B). Both the comparative top 
and side views show the similarity of the globular head structure of HA1 between a modular 
capsomere and trimeric HA. Previous findings have shown that stabilised trimeric HA, but not the 
dimeric or monomeric forms, retain the ability to bind sialic acid on red blood cells, allowing 
agglutination [21, 23]. This suggests that sialic acid-binding requires a quaternary structure composed 
of a trimer of HA, and because the modular capsomere also causes hemagglutination, it may orient 
the HA1 molecules in such a way that it mimics the relevant site in the HA trimer. 
 
Figure 4-4: Functional characterisation and homology modelling of modular capsomeres. (A) 
Hemagglutination assay of cCaptHA1, aCaptHA1, and pCaptHA1. Lines represent endpoint titres. 
(B) Homology models of CaptHA1 and native trimeric HA protein (HA PDB file 1RUZ.pdb).  
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Well-characterised cCaptHA1, aCaptHA1and pCaptHA1 were tested for their immunogenicity in 
chickens. Figure 4-5A illustrates HA1-specific antibody endpoint titres after the first immunisation 
(prime) and the second immunisation (boost) with Alhydrogel-adjuvanted vaccine candidates. No 
significant change was observed in the endpoint titre of antibody response (p < 0.05) between the 
prime and boost for groups immunised with cCaptHA1, aCaptHA1 and VP1dC capsomere. For 
pCaptHA1, the antibody endpoint titre increased from 103 (prime immunisation) to above 105 after 
the boost immunisation. The lower titre after prime immunisation is likely caused by the lower ratio 
of capsomeres to total protein in pCaptHA1 compared with the other two groups, cCaptHA1 and 
aCaptHA1, as shown in Figure 4-5A. Notably, although there were fewer capsomeres in the 
pCaptHA1 preparation, there was no difference between the titres of all groups after the boost. The 
increase of antibody titre obtained from pCaptHA1 to the same level as cCaptHA1 and aCaptHA1 
after the boost suggested fewer capsomeres in the boost still initiated a ‘maximal’ antibody titre. 
However, the presence of aggregates and bacterial contaminants in the pCaptHA1 preparation may 
also contribute to the increase in the antibody titre after the boost immunisation. Although aCaptHA1 
contained fewer capsomeres but more soluble aggregates than cCaptHA1, similar immunogenicity 
was obtained for both samples. This suggests that soluble aggregates form macromolecules that retain 
antigenic properties to enhance vigorous immune responses, possibly via protein aggregate-mediated 
B cell receptor cross-linking, as has been demonstrated in previous studies [24-26]. The bacterial 
contaminants may also elicit the immune response through germline-encoded pattern recognition 
receptors that recognise the bacterial components and lead to the activation of immune systems [27]. 
The data also suggest that a single dose at 70 g may be sufficient to induce protective immunity in 
chickens, as the boost immunisation did not significantly elevate antibody titres for vaccine groups 
cCaptHA1 and aCaptHA1. However, a single dose of 70 g pCaptHA1 may not be sufficient to 
induce protective immunity in chickens. 
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Figure 4-5: Immunogenicity of modular capsomeres. (A) HA1-specific antibody titres induced in 
chickens following two intramuscular immunisations with VP1dC capsomere and modular 
capsomeres. Statistical analysis is presented between prime and boost titres and antibody titres after 
the second immunisation (boost). **** = p < 0.0001; ns = not significant. (B) Hemagglutination 
inhibition (HI) assay results showing HI titres of prime and boost sera following immunisation with 
cCaptHA1, aCaptHA1 and pCaptHA1. Geometric mean with 95% confidence interval is presented. 
Endotoxin levels of cCaptHA1, aCaptHA1 and pCaptHA1 were 225, 39023, and 59326 EU/mL, 
respectively. Although endotoxin can evoke a pathophysiological effect through activation of the 
immune system [28], the total amount of endotoxin per dose of injection (56.25, 9755.75 and 14831.5 
EU for cCaptHA1, aCaptHA1 and pCaptHA1, respectively) was low compared with the endotoxin 
content in bacterially-produced commercial vaccines. Typhus and cholera vaccines have reported 
endotoxin levels of 1x105 and 1x106 EU/mL, respectively [29]. It is likely that chickens are less 
susceptible to endotoxins compared with mammals [30]. The amounts of endotoxin were not toxic, 
and no adverse effects were observed.  
Hemagglutination inhibition (HI) test was conducted as a surrogate for vaccine efficacy in this study. 
HI titres have been correlated to seroprotection by HI antibodies that inhibit the binding of influenza 
hemagglutinin to sialic acid on target cells, preventing virus infectivity [31]. An HI titre of 16 against 
4 HA units of antigen is considered positive for the immunoprotection of challenge chickens [19]. 
Nonetheless, HI titres ranging from 1:8 to 1:32 (geometric mean titre = 8) provided protection in 
chickens challenged with the homologous virus [11]. Figure 4-5B illustrates HI titres following prime 
and boost vaccinations with cCaptHA1, aCaptHA1 or pCaptHA1. After boost immunisation, HI titres 
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of cCaptHA1, aCaptHA1 and pCaptHA1 ranged from 1:4 to 1:256 (geometric mean = 20.7), 1:8 to 
1:512 (geometric mean = 69.8) and <1:4 to 1:256 (geometric mean = 17.7), respectively. VP1dC 
capsomere generated low HI titres (geometric mean = 1.3), as expected. The results suggest that HI 
antibodies obtained from aCaptHA1 and pCaptHA1 are likely to confer protection, as was obtained 
from the immunisation with cCaptHA1.  
This study investigated the efficacy of partially purified aCaptHA1 and crudely purified pCaptHA1 
as a vaccine antigen for AI compared with highly purified cCaptHA1, which was shown to confer 
complete protection in immunised chickens in a previous study. The results show that presence of 
soluble aggregates and low amounts of host cell contaminants do not affect the immunogenicity and 
functionality of aCaptHA1 and pCaptHA1 after two immunisations. This warrants further 
investigation to develop a simpler and cost-effective process to generate immunogenic modular 
capsomere CaptHA1 that provides protection from AI. 
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Chapter 5 
Simplified production and purification of modular capsomere-based 
vaccine for avian influenza  
The entire chapter consists of the journal article submitted as:  
Jarurin Waneesorn, Hayley K. Charlton Hume, Anton P.J. Middelberg and Linda H.L. Lua (2017). 
Simplified production and purification of modular capsomere-based vaccine for avian influenza. 
Submitted to Biotechnology and Bioengineering. (Manuscript number: 17-793) 
The following changes have been made to the text of this chapter: 
- Page, figure, section and subsection numbering and reference style were changed to be 
consistent with the rest of the thesis. 
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5.1 Abstract 
Highly pathogenic avian influenza (HPAI) is an extremely infectious disease caused by avian 
influenza A viruses. As a result of exceedingly high transmission and mortality rates, HPAI outbreaks 
have been responsible for huge economic losses in the poultry industry in both developed and 
developing countries. Although it mainly affects birds, the increasing reports of HPAI crossing the 
species barrier have fuelled major concerns that zoonotic disease may ultimately lead to a devastating 
influenza pandemic among humans. Given the persistent threat to human health and the increasing 
economic effect on the poultry industry, there is a pressing need to address the underlying problem-
that is, the lack of effective control measures. Poultry vaccination significantly decreases the risk of 
viral transmission and transfer to humans when the vaccine is matched to the pathogenic virus. In 
conjunction with appropriate biosecurity means, it can be instrumental in controlling the rapid spread 
of avian influenza. A recently developed capsomere-based influenza vaccine proved to be 100% 
protective against HPAI H7N7 virus challenge in chickens. The production and chromatographic 
process by which this vaccine was produced is not economically attractive for use in the cost-sensitive 
poultry industry. Here, the capsomere vaccine candidate was re-engineered, and a simple, non-
chromatographic purification process was developed. The bacterially-produced, non-fusion-tagged 
modular capsomere presenting a truncated form of the globular head of hemagglutinin (CaptHA1), 
can be selectively purified by precipitation. Direct comparison with an unoptimised chromatographic 
process reveals at least a thirty-fold increase in the final yield of CaptHA1 using the simplified 
column-free process, as well as the retention of CaptHA1 functional properties. While further 
optimisation of the current process may result in further improved yield and purity, this study 
describes a simplified process that is suitable for a rapidly produced, low-cost industrial poultry 
vaccine.  
5.2 Introduction 
Highly pathogenic avian influenza (HPAI) remains a major concern for the world economy and 
human health. Outbreaks of HPAI result in a significant loss of poultry through infection-induced 
mortality or culling (to control viral transmission), thus leading to widespread devastation throughout 
the poultry industry [1, 2]. The increased prevalence of HPAI, combined with the mutation-prone 
nature of the virus, greatly increases the potential for viral spread to humans, raising genuine concerns 
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of a human influenza pandemic [3, 4]. The lack of effective measures to control HPAI within the 
avian population highlights the risk of future influenza pandemics and further economic loss and is 
driving the search for a suitable poultry vaccine. Studies suggest that when used in conjunction with 
biosecurity means, appropriate vaccine use would be a powerful tool to control the spread of avian 
influenza [5, 6]. 
Virus-like particle (VLP) vaccine technology offers the potential to manufacture rapid response 
vaccines [7]. A modular capsomere platform based upon the major structural protein of murine 
polyomavirus, VP1, has been developed as a means of rapid vaccine delivery [8]. This platform, 
termed VP1dC, lacks the 63 C-terminal residues of VP1 that are responsible for mediating its 
assembly into mature VLPs. Consequently, assembly is limited to pentameric capsomeres comprising 
five identical copies of VP1dC. VP1dC was recently engineered to display a structurally designed 
truncation of the globular head of influenza hemagglutinin (tHA1) at its C-terminus for the production 
of a modular capsomere (CaptHA1) influenza vaccine in Escherichia coli (E. coli) [9]. Consistent 
with previous work on VP1, a GST-tag was fused to the N-terminus of the protein [9]. The resulting 
GST-tagged capsomere (GST-CaptHA1) comprised five copies of GST-tagged VP1dC-tHA1. 
Chromatographically purified modular capsomere (CaptHA1) demonstrated high immunogenicity 
and conferred 100% protection against challenge with HPAI H7N7 virus in chickens, demonstrating 
the potential of this molecular construct as an avian influenza vaccine [9].  
The final yield of CaptHA1 was surprisingly low. These low protein expression levels were further 
exacerbated by poor affinity binding of the macromolecular construct, as noted previously for 
capsomeres fused with GST [10]. Yield declined further as a result of capsomere aggregation 
following GST-removal in the standard buffer. This resulted in just 2% of modular capsomeres being 
recovered under standard process conditions with this construct (unpublished data). 
Purification using chromatography can account for up to three-quarters of the total operating cost of 
vaccine production [11]. High costs associated with affinity media and the complexities of GST 
removal [10] make the multistep chromatography method used to prepare CaptHA1 unsuitable for 
the production of a low-cost poultry vaccine. Employing cheaper, non-chromatographic purification 
methods would be enabling for low-cost poultry vaccine markets. Previous studies from our 
laboratory have shown that capsomere-based vaccines can be crudely purified using a selective 
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salting-out precipitation method [12, 13]. Importantly, capsomeres purified by precipitation retain 
their immunogenicity, alleviating the need for a GST-tag and subsequent chromatographic 
purification. Selective precipitation is widely used in the downstream processing of vaccines and 
other biological products. Using salts or polymers as precipitants, target proteins are selectively 
separated and concentrated from whole lysed cell preparations. In contrast to highly purified 
preparations using chromatography approaches, precipitation increases the presence of host 
contaminants. However, a recent study demonstrates that such contaminants do not diminish, and 
may actually enhance, vaccine efficacy [12].  
In this study, the production and purification process of a CaptHA1 vaccine candidate was simplified 
by eliminating GST fusion protein production and adopting a simple non-chromatographic 
purification method. Molecular engineering techniques were undertaken to generate soluble and 
stable, non-tagged capsomeres displaying tHA1. Following expression in E. coli, capsomeres were 
purified by selective precipitation. This method increased the final capsomere yield by more than 30 
times when compared with the previous method using GST-affinity chromatography. More 
importantly, we demonstrate that the capsomere structural integrity is retained. This simplified 
process contributes to the rapid production of a modular capsomere-based strain-matched vaccine to 
the avian influenza virus. 
5.3 Materials and methods 
5.3.1 Plasmid construction 
Expression plasmid for GST-tagged modular capsomere presenting HA1(44-268), from influenza A 
strain A/Puerto Rico/8/34 (H1N1), designated as GST-CaptHA1, was generated as previously 
described [9]. Murine polyomavirus VP1dC sequence (VP1 sequence lacking 63 amino acids at its 
C-terminal) was cloned into the first multiple cloning site (MCS1) of pETDuet-1 (Novagen, WI) 
between the NcoI and NotI restriction sites. This construct was used for the expression of non-tagged 
capsomeres (CapVP1dC). Plasmid for the expression of non-tagged capsomeres presenting HA1(44-
268) (CaptHA1) was generated by inserting the VP1dC-GSA-HA1(44-268) sequence, amplified from the 
GST-CaptHA1 plasmid above, into the second multiple cloning site (MCS2) of pETDuet-1 between 
the NdeI and PacI restriction sites. A construct for the dual expression of both VP1dC and VP1dC-
tHA1 proteins was generated by inserting the VP1dC sequence into the MCS1 of the VP1dC-tHA1 
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pETDuet-1 plasmid (described above) between the NcoI and NotI restriction sites. This construct was 
used for the expression of mixed modular capsomeres (mCap). All cloned constructs were generated 
by the Protein Expression Facility, The University of Queensland, Australia. DNA sequences of all 
constructs were verified by DNA sequencing (AGRF, Brisbane, Australia).  
5.3.2 Protein expression 
GST-tagged modular capsomere protein (GST-CaptHA1) was expressed in E. coli strain Rosetta 
(DE3) pLysS, as described previously [9, 14]. Expression constructs for CapVP1dC, CaptHA1 and 
mCap were transformed separately into chemically competent E. coli strains; Rosetta (DE3) pLysS 
cells (Novagen, San Diego, CA), Rosetta 2 (DE3) cells (Novagen, San Diego, CA), and SHuffle T7 
Express cells (New England Biolabs GmbH, Germany). Transformed Rosetta (DE3) pLysS and 
Rosetta 2 (DE3) cells were grown separately in baffled flask at 37 C, 180 rpm to an OD600 of 0.5 
using Terrific Broth (TB) medium containing 50 µg.mL-1 ampicillin (aMResco, Solon, OH) and 34 
µg.mL-1 chloramphenicol (Astral Scientific Pty Ltd, Gymea, NSW, Australia). For protein 
expression, cultures were induced with 0.2 mM isopropyl--D-thiogalactopyranoside (IPTG) (Astral 
Scientific Pty Ltd, Gymea, NSW, Australia), grown at 25 C and harvested after 16 h. Transformed 
SHuffle T7 Express cells were grown separately at 37 C to OD600 of 0.5 using TB medium containing 
50 µg.mL-1 ampicillin (aMResco, Solon, OH). For protein expression, cultures were induced with 1 
mM IPTG, grown at 25 C and harvested after 16 h.  
5.3.3 Chromatographically purified modular capsomere (GST-CaptHA1) 
Chromatographically purified GST-CaptHA1 was prepared as described previously [9, 14]. Sample 
was stored at -80 C until further use.  
5.3.4 Crudely purified modular capsomere (CapVP1dC, CaptHA1 and mCap) using Na2SO4 
Cell pellets from 50 mL cultures of CapVP1dC, CaptHA1 and mCap were resuspended separately in 
15 mL L-buffer (40 mM Tris, 500 mM NaCl, 1 mM EDTA, 5% (v/v) glycerol, 5 mM DTT, pH 8.5). 
Cells were lysed by sonication (Branson Sonifier 450 ultrasonicator, Branson Ultrasonics, CT, USA) 
at an energy output of 60 W for four bursts of 40 sec, and cell lysates were clarified by centrifugation 
(25,200 x g, 4C, 20 min). Soluble protein was precipitated at different concentrations of Na2SO4 
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(0.6, 0.8, 0.9 and 1 M) for 2 h at room temperature. Following centrifugation (25,200 x g, 4C, 15 
min), the supernatant was removed and the precipitate resuspended with L-buffer. The resuspension 
was further centrifuged (25,200 x g, 4C, 5 min), and the supernatant containing the soluble 
precipitate was taken for further analysis.  
5.3.5 Crudely purified modular capsomere (CapVP1dC, CaptHA1 and mCap) using PEG 6000 
Cell pellets from 50 mL cultures of CapVP1dC, CaptHA1 and mCap were resuspended separately in 
15 mL of L-buffer (40 mM Tris, 500 mM NaCl, 1 mM EDTA, 5% (v/v) glycerol, 5 mM DTT, pH 
8.0). Cells were lysed by sonication as above, and cell lysates were clarified by centrifugation (12,000 
x g, 4C, 20 min). Soluble protein was precipitated at different concentrations of polyethylene glycol 
(PEG) 6000 (2, 5, 8 and 10% w/v) (Chem-Supply Pty Ltd) for 2 h at room temperature. Following 
centrifugation (12,000 g, 4C, 30 min), the supernatant was removed and the precipitates resuspended 
with L-buffer. The resuspension was further centrifuged (12,000 x g, 4C, 20 min) and the supernatant 
was taken for further analysis. Protein concentrations were determined using Coomassie (Bradford) 
Protein Assay Kit (Thermo Fisher Scientific). 
5.3.6 Capsomere Characterisation 
Qualitative analysis of all protein samples was performed using standard SDS-PAGE [15], Western 
blot and dot blot analysis. Western blot was performed as previously described [9], except chicken 
anti-HA1 antisera and horseradish peroxidase (HRP)-conjugated rabbit anti-chicken IgG (A9046; 
Sigma-Aldrich, USA) were used as the primary and secondary antibody, respectively. For dot blot 
analysis, antigens (4 µg) were applied onto a PVDF membrane, blocked with 5% skim milk powder 
in 0.1% PBS-T buffer and probed with chicken anti-HA1 antisera. HRP-conjugated rabbit anti-
chicken IgG (A9046; Sigma-Aldrich) was used for detection via chemiluminescence. 
5.3.7 Hemagglutination assay 
Hemagglutination assay was conducted with starting protein concentration 0.4 mg.mL-1 as described 
previously (Section 2.3.4, p. 10-11) [16]. 
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5.4 Results and discussion 
VP1dC capsomere platform is based upon the VP1 structural protein of murine polyomavirus. To 
generate a capsomere-based influenza vaccine, VP1dC was recently engineered to present a 
structurally designed truncation of the globular head of influenza hemagglutinin (tHA1) at its C-
terminus (Figure 5-1). Modularisation at this flexible site allows antigenic module tHA1 to form a 
stable domain adequately separated from the base module VP1dC [9]. VP1dC-tHA1 was previously 
expressed as a GST fusion proteins to enhance protein solubility and aid affinity purification. When 
expressed in E. coli, this modular protein self-assembles into a capsomere composed of five 
monomers of GST-tagged VP1dC-tHA1 (GST-CaptHA1) (Figure 5-1A). Low capsomere yield and 
high costs associated with GST-affinity purification highlighted the need to optimise the production 
process. To remove complex chromatography steps, the VP1dC platform was redesigned to present 
tHA1 at its C-terminus without a GST-tag (VP1dC-tHA1), ultimately producing a non-tagged 
capsomere (CaptHA1) (Figure 5-1B). The globular head of hemagglutinin is highly insoluble when 
expressed in E. coli, and is reported to form inclusion bodies [17-19]. The strategy for producing 
fusion protein GST-VP1dC-tHA1 was postulated to enhance the solubility of tHA1 in E. coli. Thus, 
removing the GST solubility tag may increase protein misfolding of VP1dC-tHA1 and lead to 
capsomere instability. We hypothesised that titrating the tHA1 content within each capsomere would 
maintain the structural integrity and protein stability of CaptHA1. A dual expression strategy, 
employed to reduce steric hindrance of a large rotavirus antigen VP8* on the surface of VP1 
capsomere [13, 20], was used here to reduce the number of tHA1 modules per capsomere. The dual 
expression construct was designed to co-express VP1dC and modular VP1dC-tHA1. The resulting 
population of capsomeres, denoted mCap, potentially comprised various ratios of VP1dC:VP1dC-
tHA1 (5:0, 4:1, 3:2, 2:3, 1:4, 0:5), as shown in Figure 5-1C. 
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Figure 5-1: Engineering modular capsomere presenting tHA1 (CaptHA1). (A) GST-CaptHA1, each 
modular capsomere before and after removal of GST-tag, contains five copies of GST-tagged-VPdC-
tHA1 and VP1dC-tHA1, respectively. (B) CaptHA1, each modular capsomere contains five copies of 
VP1dC-tHA1. (C) mCap, modular capsomeres composed of different ratios of VP1dC to VP1dC-
tHA1 (0:5, 1:4, 2:3, 3:2, 4:1 or 5:0). 
The expression of non-tagged CaptHA1 and mCap was examined in three E. coli strains, namely 
Rosetta (DE3) pLysS, Rosetta 2 (DE3) and SHuffle T7 Express cells (Figure 5-2). High expression 
of CaptHA1 and mCap was observed in all host strains. In both Rosetta strains, the CaptHA1 soluble 
protein was significantly reduced compared with the total protein, suggesting that the CaptHA1 
protein misfolded during expression (Figure 5-2A). In contrast, approximately 70% of the total 
CaptHA1 protein was soluble in SHuffle T7 Express cells. This host strain is specifically engineered 
to enhance disulfide bonding in the cytoplasm [21]; thus, it may have contributed to the correct 
folding and stability of tHA1, which contains two disulfide bonds. High solubility of mCap was 
observed in all host strains, with Rosetta 2 (DE3) showing the highest levels (Figure 5-2B). This 
observation supports the hypothesis that co-expression of VP1dC and VP1dC-tHA1, which titrates 
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tHA1 content per capsomere, alleviates the steric effects of tHA1 within the capsomere. This allows 
capsomere structural integrity and stability to be maintained, in the same way we discovered for 
rotavirus VP8* [13]. Consequently, CaptHA1 in SHuffle T7 Express and mCap in Rosetta 2 (DE3) 
were chosen for further investigation. 
 
Figure 5-2: Modular capsomere protein expression and solubility. (A) CaptHA. (B) mCap in E.coli 
strain Rosetta (DE3) pLysS, Rosetta 2 (DE3) or SHuffle T7 Express. Lanes: (M) molecular weight 
marker, (P) pre-induced lysate, (T) total lysate, (S) soluble lysate. 
Selective salt precipitation can be used to enrich target proteins in complex preparations [12, 22]. 
Sodium sulfate (Na2SO4) at 1 M concentration was used to precipitate CaptHA1 and mCap. SDS-
PAGE analysis of precipitated proteins showed an enrichment of CaptHA1 and mCap proteins, as 
demonstrated by dominant bands observed at the expected sizes for VP1dC-tHA1 (61.97 kDa) for 
CaptHA1 (Figure 5-3A), and VP1dC-tHA1 and VP1dC (35.2 kDa) for mCap (Figure 5-3B). E. coli 
host proteins were co-precipitated, but to a lesser degree than the CaptHA1 and mCap target proteins. 
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The structural integrity of modular capsomeres post-precipitation was first examined using analytical 
size exclusion chromatography (SEC-HPLC). Figure 5-3C shows the SEC-HPLC analysis of the 
CaptHA1 and mCap precipitates. For the CaptHA1 precipitate, two dominant peaks were observed 
at approximately 16 min and 22 min, corresponding to the elution of soluble aggregates and 
capsomeres, respectively. In contrast, only one dominant peak at 16 min, corresponding to soluble 
aggregates, was observed for the mCap precipitate. Only a modest capsomere peak was observed for 
the mCap precipitate. Fractions representing peaks were collected and analysed by SDS-PAGE 
(Figure 5-3A and 5-3B). The CaptHA1 capsomere peak fraction contained the majority of the VP1dC-
tHA1 target protein (Figure 5-3A, Lane Ca), while the majority of the VP1dC-tHA1 and VP1dC 
target proteins in the mCap fractions were contained in the aggregate peak fraction (Figure 5-3B, 
Lane Ag). Taken together, these results suggest that precipitation using Na2SO4 affects the structural 
integrity of mCap but not that of CaptHA1. Contaminating E. coli host proteins were observed in the 
capsomere peak fractions for both CaptHA1 and mCap; however, distinct differences were observed. 
An intense band at approximately 75 kDa was observed in the capsomere peak fraction of CaptHA1, 
but not in the capsomere peak fraction of mCap. It was hypothesised that this is the heat shock 
chaperone protein, hsp70, aiding in capsomere stability. As CaptHA1 presented mostly as stable 
modular capsomeres, it was selected for continued investigation. Given the high levels of soluble 
aggregates observed in the mCap precipitate and the complexities associated with mixed modular 
capsomeres, no further studies were performed with mCap.  
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Figure 5-3: Analysis of modular capsomere following precipitation using 1 M Na2SO4. (A) SDS-
PAGE analysis of CaptHA1. (B) SDS-PAGE analysis of mCap. (C) Size exclusion chromatogram 
(analytical SEC-HPLC) of CaptHA1 and mCap. Lanes: (M) molecular weight marker, (PC) protein 
precipitate, (Ag) SEC fraction corresponding soluble aggregate peaks, (Ca) SEC fraction 
corresponding capsomere peaks. 
To further improve on the precipitation of CaptHA1, Na2SO4 and PEG 6000 were tested at different 
concentrations. PEG 6000 is commonly used to concentrate viruses and precipitate a variety of 
proteins [23-26]. Figure 5-4A shows SDS-PAGE analysis of CaptHA1 precipitation using 1, 0.9, 0.8 
and 0.6 M Na2SO4. Precipitation of CaptHA1 was observed at concentrations equal to or greater than 
0.8 M Na2SO4. Co-precipitation of contaminants increased with increasing concentrations of Na2SO4. 
High CaptHA1 yield was recovered from precipitation using 1 M Na2SO4 while a moderate amount 
of CaptHA1 remained in the supernatant fraction. Figure 5-4B shows SDS-PAGE analysis of 
CaptHA1 precipitation using 10, 8, 5 and 2% PEG 6000. Precipitation of CaptHA1 was observed at 
greater than or equal to 5% PEG 6000. Optimal yield of CaptHA1 was obtained with 8% PEG 6000. 
As observed for Na2SO4 precipitation, contaminating E. coli host proteins were precipitated alongside 
CaptHA1.  
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Figure 5-4: Optimisation of selective precipitation using Na2SO4 and PEG 6000. (A) SDS-PAGE 
analysis of precipitation using 1, 0.9, 0.8 and 0.6 M Na2SO4. (B) SDS-PAGE analysis of precipitation 
using 10, 8, 5 and 2% PEG 6000. Lanes: (M) molecular weight marker, (Su) supernatant, (PC) 
protein precipitate. 
CaptHA1 precipitated by either 1 M Na2SO4 or 8% PEG 6000, was characterised by SEC and SDS-
PAGE. Figure 5-5A and 5-5B show SEC chromatograms of 1 M Na2SO4- and 8% PEG 6000- 
precipitated CaptHA1, respectively. As observed above, capsomeres eluted at approximately 22 min, 
and soluble aggregates at approximately 16 min. As shown by SDS-PAGE analysis, an intense protein 
band was observed at the expected molecular weight for VP1dC-tHA1 (61.97 kDa) in both the 
Na2SO4 and PEG 6000 precipitates. The protein band at 75 kDa in the Na2SO4 precipitation sample, 
posited to be hsp70, was not observed in the PEG-precipitated sample. This highlights the selective 
nature of the different precipitants as a result of their specific physicochemical properties. An SEC 
chromatogram shows that PEG-precipitated CaptHA1 contains several peaks in addition to the main 
capsomere and aggregate peaks observed from 1 M Na2SO4-precipitated CaptHA1. This may be 
explained by the anomalous chromatographic behaviour of PEG-proteins or PEG-sodium ion 
complexes on SEC [27-29] or PEG variants and other impurities. Detailed characterisation of these 
peaks using alternative techniques such as liquid chromatography–mass spectrophotometry (LC/MS) 
or SEC with multi-angle light scattering (SEC-MALS) would help to determine such peaks and 
support alternative explanations. 
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Figure 5-5: Characterisation of precipitated CaptHA1. (A) 1 M Na2SO4-precipitated CaptHA1 (B) 
8% PEG 6000-precipitated CaptHA1. Size exclusion chromatogram (left) showing capsomeres 
separated from aggregates. SDS-PAGE analysis (right) showing lanes: (PC) protein precipitate, (Ag) 
SEC fraction corresponding soluble aggregate peaks, (Ca) SEC fraction corresponding capsomere 
peaks. 
To confirm protein identity, precipitated CaptHA1 was further characterised using Western blot and 
dot blot analysis. Theoretical molecular weights of VP1dC, VP1dC-tHA1 and an insect cell-derived 
HA1 protein (used as control) are 35.2, 61.97 and 37.6 kDa, respectively. SDS-PAGE analysis 
showed that protein bands were detected at the expected molecular weights for VP1dC and VP1dC-
tHA1 (Figure 5-6A). In line with previous studies showing glycosylation of insect cell-derived HA1, 
control HA1 was detected at a larger molecular weight than predicted [30-32]. Precipitated CaptHA1, 
chromatographically purified CaptHA1 and HA1 control were detected by Western blot and dot blot 
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analyses (Figure 5-6B and 5-6C) using anti-HA1 chicken sera, demonstrating recognition in both the 
denatured (Figure 5-6B) and native (Figure 5-6C) forms. VP1dC (base module used as negative 
control) was not detected by either Western blot or dot blot analyses using anti-HA1 chicken sera. 
Receptor binding properties of precipitated CaptHA1 were analysed using a hemagglutination assay 
(Figure 5-6D). Strong hemagglutination with endpoint titres of 512 and 1024 were observed for PEG- 
and Na2SO4- precipitated CaptHA1, respectively. These titres were higher than chromatographically 
purified CaptHA1 (endpoint titre of 256). In contrast, no hemagglutination was observed for 
precipitated CapVP1dC negative control. The results indicate that precipitated CaptHA1 at the same 
starting protein concentration (0.4 mg.mL-1) exhibits strong receptor binding properties, suggesting 
that tHA1 modules retain their native structure, enabling the binding of modular capsomeres to sialic 
receptors on the surface of the red blood cells. Further, these results suggest that precipitated 
CaptHA1 is just as effective as chromatographically purified CaptHA1. The focus of this study is to 
develop both expression and purification methods for simplified processing of CaptHA1; thus, the 
protective efficacy of precipitated CaptHA1 in chickens to challenge with HPAI virus is highly 
relevant and will be determined in future studies. 
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Figure 5-6: Functional characterisation of precipitated CaptHA1. (A) SDS-PAGE analysis. (B) 
Western blot analysis. (C) Dot blot analysis with HA1 specific antibody detected CaptHA1 and HA1 
protein. (D) Hemagglutination assay of precipitated CaptHA1, chromatographically purified 
CaptHA1 and CapVP1dC. Lines represent endpoint titres. 
To simplify the production process of CaptHA1 for use as an avian influenza vaccine, an integrated 
approach was adopted to express non-tagged modular capsomeres and eliminate the use of 
chromatography for purification. Figure 5-7 compares the previously established methodologies for 
the production of chromatographically purified CaptHA1 (Figure 5-7A) with the simplified process 
developed in this study (Figure 5-7B). The approach using non-tagged CaptHA1 expression removes 
the need for enzymatic tag removal and isolation of tag-free target proteins via SEC, directly 
eliminating the high costs associated with these processing steps. From 1 L cell culture, the yield of 
the tag-free CaptHA1 target protein, following TEVp digestion and SEC and using the unoptimised 
GST expression and purification method, was approximately 0.22 mg with a purity of 91%. In 
contrast, CaptHA1 recovered following precipitation with Na2SO4- and PEG- produced target protein 
yields of 36 mg and 48 mg, respectively. However, the purity of precipitated CaptHA1 is much lower 
than the chromatographically purified CaptHA1 and, as observed from the SDS-PAGE analysis 
(Figure 5-6A), the purity of Na2SO4-precipitated CaptHA1 is lower than PEG-precipitated CaptHA1. 
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An in vivo study by Wibowo and colleagues [12] demonstrated that the presence of E. coli host 
contaminants did not adversely affect the immunogenicity of a vaccine candidate, but in fact 
suggested that the presence of an optimal amount of contaminating host-derived protein with adjuvant 
may drive a preferential immune response. This may be beneficial, particularly for veterinary 
vaccines, where purity considerations are less constraining. 
 
Figure 5-7: Process for modular capsomere production. (A) Previously established process for 
producing chromatographically purified CaptHA1. (B) Simplified process for producing crudely 
purified CaptHA1.  
This study details a simpler production process for obtaining purified CaptHA1, which is superior to 
the previously established chromatographic approach in terms of ease of production and increased 
protein yield. These improvements are achieved at the expense of purity, which may be desirable for 
veterinary vaccines, noting the adjuvanting effect of contaminants. This process eliminates the tag 
cleavage steps and complex chromatography steps, namely GST-affinity purification and subsequent 
SEC. The process also demonstrates that higher target protein yield provide cost advantages for 
vaccine provider. Through the redesign of the molecular construct and the adoption of selective 
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precipitation as the method for purification, the yield of CaptHA1 is improved by more than 30-fold. 
Moreover, precipitated CaptHA1 is shown to retain its biological properties. Further studies will aim 
to improve CaptHA1 yield using high-throughput experimentation systems [33, 34] and a fed-batch 
high-cell-density process [35] as shown for VP1 gram-per-litre expression yield. Purity of CaptHA1 
may improve through further optimisation of the simple and scalable selective precipitation method 
[12, 13, 36] or through the implementation of membrane filter-based technologies [37, 38]. Given the 
functional activity demonstrated in this study, future work will also examine the immunogenicity of 
crudely purified CaptHA1 and its protective efficacy in chickens, in particular, with animal-relevant 
adjuvants such as oil-based adjuvants [39]. 
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Chapter 6 
Conclusions and future work 
6.1 Summary of research findings 
Avian influenza (AI) remains a worldwide threat to the poultry industry and human health. The 
continuing outbreaks of highly pathogenic avian influenza (HPAI) across numerous continents have 
necessitated the implementation of appropriate strategies to control the spread of the virus. 
Vaccination is a powerful tool for managing viruses in poultry. The use of vaccination programmes, 
in conjunction with biosecurity means, offers a potential measure for controlling the disease [1]. 
However, the limitations of current egg- and cell culture-based commercialised AI vaccines-in 
particular, slow production time-underline the need to improve vaccine manufacturing processes to 
successfully respond to HPAI outbreaks.  
Microbial-based expression systems are successfully used for the production of licensed vaccines for 
hepatitis E virus [2] and human papillomavirus [3, 4]. Such technologies allow vaccines to be 
manufactured at a speed and scale that is unachievable using egg- and cell culture-based systems. A 
bacterial-based expression system also allows an effective strain-matched vaccine to be produced 
within weeks of the identification of the new strain. In this thesis, to address current AI vaccine 
manufacturing limitations, a novel capsomere platform based upon the VP1 capsid protein of murine 
polyomavirus, was designed and expressed in E. coli. This rapidly produced, scalable platform 
(VP1dC) presents a low-cost alternative for vaccine manufacturing.  
The experimental work described in this thesis was designed to investigate three key aspects in the 
development of a modular capsomere as an influenza vaccine candidate for application in poultry. 
These are outlined below: 
(i) Structure-based design of modular capsomeres (Chapter 3): This study evaluated the 
potential of a structure-based designed modular capsomere presenting modified HA1 as a 
poultry vaccine candidate.  
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(ii) Characterisation of modular capsomeres purified using simpler methods (Chapter 4): This 
study investigated the immunogenicity of E. coli-produced modular capsomere partially 
purified by chromatographic methods or crudely purified using selective precipitation 
techniques. 
(iii) Simplified production and purification of modular capsomeres (Chapter 5): The 
production process of modular capsomeres was simplified by adopting an integrated 
approach to generate non-tagged modular capsomeres and replace chromatographic 
methods with simpler selective precipitation methods suitable for cost-effective vaccine 
manufacturing for price-sensitive markets. 
The following sections summarise the key findings obtained from the experimental work in this study. 
6.1.1 Structure-based design of modular capsomeres 
This study evaluated the potential of a novel structure-based designed modular capsomere as an 
influenza vaccine candidate. Rational design of both the capsomere platform and HA1 was 
undertaken to overcome capsomere instability. A VP1 platform lacking the last 63 amino acids but 
retaining the native 28 amino acids at its N-terminus with two insertion sites at its N- and C-termini, 
respectively was designed. 
Flexible linkers GSAGSAAGSGEF (GSA linkers) were also inserted at both termini to provide 
structural separation between the platform and insert. This new capsomere platform was designated 
as VP1dC (Figure 3-1A). HA1, derived from human influenza A strain PR8 H1N1, was redesigned 
to improve protein solubility by selectively removing the HA1 tail. Secondary structural elements 
within the globular head of HA1, responsible for the formation of conformational epitopes, were thus 
retained. Three versions of this truncated HA1 (tHA1) were designed; HA132-308 (tHA1-1), HA140-277 
(tHA1-2) and HA144-268 (tHA1-3). Each version of tHA1 contained different secondary structural 
elements. Each version of tHA1 and unmodified HA1 (amino acid 1 to 36) were then independently 
modularised into either the N- or C-terminus of VP1dC, resulting in eight modular VP1dC-HA1 
constructs: four constructs presenting HA1 at the N-terminus of VP1dC (HA1-N, tHA1-1N, tHA1-
2N and tHA1-3N) and four constructs presenting HA1 at the C-terminus of VP1dC (HA1-C, tHA1-
1C, tHA1-2C and tHA1-3C). These modular constructs were self-assembled into capsomeres 
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consisting of pentamers of each VP1dC-HA1 and were expressed as GST-tagged proteins in E. coli 
to improve protein solubility and aid protein purification. 
The expression and solubility levels of each GST-tagged modular capsomere were examined by SDS-
PAGE analysis. The site of antigen modularisation, the N- or C-terminus, was shown to have little 
effect on capsomere expression and solubility. In contrast, the expression and solubility of modular 
capsomeres were adversely affected by increases in molecular weight and the presence of secondary 
structural elements within the HA1 module.  
To investigate the stability of modular capsomeres using SEC, the GST-tagged modular capsomeres 
were purified by GST-affinity chromatography followed by enzymatic release of GST. Non-tagged 
modular capsomeres were then separated from GST tags and protein aggregates using SEC. The 
highest capsomere yield was obtained from CaptHA1-3C, which is a pentamer of VP1dC-tHA1-3C, 
suggesting that modularisation of HA1 on the C-terminus of VP1dC facilitated the recovery of stable 
capsomeres. These results suggest that modularisation at the C-terminus allows greater separation 
between the platform and insert than modularisation at the N-terminus. It is likely that site C is more 
flexible than site N, thus avoiding the steric barrier between each protein domain, and preventing 
protein aggregation. 
Western blot analysis of purified CaptHA1-3C showed specific detection of VP1dC-tHA1-3C 
modules by mouse anti-HA sera. A hemagglutination assay was performed to assess the receptor 
binding properties of purified CaptHA1-3C, demonstrating strong hemagglutination with endpoint 
titre of 1024. Together, these results suggest that HA1 modules present in purified CaptHA1-3C 
maintain their native structure, enabling binding to sialic acid on the surface of red blood cells.  
An in vivo immunogenicity study conducted in chickens demonstrated that immunisation with two 
doses of purified CaptHA1-3C contains HA144-268 from PR8 H1N1, adjuvanted with aluminium 
hydroxide (Alhydrogel), inducing high levels of HA1-specific antibody endpoint titres (almost 105). 
A protective efficacy study performed with CaptHA1-3C contains HA145-262 from HPAI virus strain 
H7N7, showing that chickens immunised with two doses of adjuvanted CaptHA1-3C45-262 
(H7N7CaptHA1-3C) were completely protected against challenge with the homologous live virus. 
The immunogenicity and protective efficacy data illustrate the potential of E. coli-produced 
CaptHA1-3C as a poultry vaccine candidate. 
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To the best of our knowledge, this study is the first modularisation of a re-engineered large antigenic 
HA1 module on the capsomere platform. This modular capsomere was successfully expressed in E. 
coli without the need for protein refolding. The immunogenicity and protective efficacy of this 
modular capsomere indicated its potential as a vaccine candidate. In addition, this capsomere 
platform, which offer a fast, low-cost and high-yield expression system, can be quickly adapted to 
match circulating influenza strains.  
6.1.2 Characterisation of simpler purified modular capsomeres  
The results presented in Chapter 3 support CaptHA1-3C as a promising vaccine candidate. However, 
high costs associated with the current chromatographic purification process make it unfeasible for the 
development of a low-cost poultry vaccine. Studies have demonstrated the high immunogenicity of 
precipitated capsomeres and VLPs (solubilised capsomeres and VLPs purified by precipitation) as 
vaccine candidates against influenza and rotavirus [5, 6]. Thus, simpler selective precipitation 
protocols may offer alternative methods of purification. However, selective precipitation increases 
impurities such as protein aggregates and other E. coli protein contaminants in the vaccine 
preparation. These host cell-derived impurities can enhance vaccine immunogenicity [7]. Therefore, 
this study, aimed to investigate the effect of such impurities on the immunogenicity of the CaptHA1-
3C vaccine candidate. 
CaptHA1-3C (hereafter CaptHA1) was purified using the chromatographic method (cCaptHA1). 
Two additional purification processes were used to obtained less pure CaptHA1 preparations, and the 
components of each preparation were then characterised. The immunogenicity and safety of each 
preparation was evaluated and compared with cCaptHA1. 
CaptHA1 contains five VP1 monomers, each displaying a C-terminal tHA1 (Figure 4-1). The 
chromatographically purified CaptHA1 (cCaptHA1) contains mainly pure capsomeres 
(approximately 90%). The chromatographically partially purified CaptHA1 (aCaptHA1) contains 
around a 1:1 ratio of pure capsomeres to soluble aggregates, while pCaptHA1, which is crudely 
purified by selective precipitation, contains mostly soluble aggregates, some E. coli host proteins and 
a small amount of capsomeres.  
 111 
 
Western blot analysis showed that both aCaptHA1 and pCaptHA1 were recognised by mouse anti-
HA sera. Strong hemagglutination of aCaptHA (endpoint titre of 2048) was observed in a 
hemagglutination assay. An endpoint titre of 32 was shown for pCaptHA1, which was lower than 
both aCaptHA1 and cCaptHA1 (endpoint titre of 1024). These results suggest that the presence of 
soluble aggregates and E. coli contaminants do not inhibit the hemagglutination ability of CaptHA1. 
Thus, aCaptHA1 and pCaptHA1 are likely to present intact structures similar to cCaptHA1, 
resembling the native structure of trimeric HA containing both the globular head (HA1) and the stem 
(HA2), as shown in Figure 4-4B. However, the endpoint titre obtained from pCaptHA1 was much 
lower than those obtained from cCaptHA1 and aCaptHA1. It is hypothesised that the lower amounts 
of CaptHA1 present in pCaptHA1. It is hypothesised that the lower amounts of CaptHA1 present in 
pCaptHA1 resulted in there being fewer HA1 sites to bind to sialic acid on the red blood cells. 
The presence of endotoxin in injectable vaccines and its toxicity is of concern in animals and humans 
[8-10]. Therefore, prior to the in vivo immunogenicity study, bacterial endotoxins were removed from 
cCaptHA1, aCaptHA1 and pCaptHA1 using anion exchange. The total amount of endotoxin per 
injection dose for cCaptHA1, aCaptHA1 and pCaptHA1 was considered low compared with the 
endotoxin levels present in other bacterially-produced commercial vaccines for human use [11]. No 
pathophysiological effects were observed in the birds after immunisation, suggesting that the amount 
of endotoxin present in each dose was not toxic. 
The in vivo immunogenicity of aCaptHA1 and pCaptHA1 in chickens was evaluated and compared 
with cCaptHA1. Each vaccine candidate was adjuvanted with Alhydrogel and administered in two 
doses. The aCaptHA1 induced a strong antibody of more than 105 endpoint titres, which was superior 
to that obtained for cCaptHA1. The pCaptHA1 induced strong antibody responses of almost 105 
endpoint titres, similar to titres obtained for cCaptHA1. Interestingly, aCaptHA1, which contained 
high levels of soluble aggregates, elicited a higher immune response than cCaptHA1, which contained 
mostly pure capsomeres. It is hypothesized that the robust immune responses raised against 
aCaptHA1 resulted from protein aggregate-mediated B cell receptor cross-linking [12, 13]. It is also 
hypothesised that pCaptHA1, which contained mostly soluble aggregates, small molecular weight 
contaminants of E. coli proteins and a small amount of capsomeres, provoked strong immune 
responses cause by a synergistic effect resulting from an optimal amount of contaminants in the 
vaccine formulation [5].  
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Given that HI titres have been shown to correlate with protection against virus infection [14], a 
hemagglutination inhibition (HI) test was used as a surrogate assay to assess vaccine efficacy. A HI 
titre with a geometric mean of 8 is reported to fully protect chickens against challenge with the 
homologous live virus [15]. HI titres obtained from aCaptHA1 and pCaptHA1 (geometric mean titre 
= 69.8 and 17.7, respectively) are therefore likely to confer protection as was obtained from 
immunisation with the cCaptHA1 (geometric mean titre = 20.7).  
The data presented in this study suggest that soluble aggregates, bacterial contaminants and 
endotoxins present in the vaccine formulation do not impair vaccine efficacy. Rather, an optimal 
amount of contaminants is likely to contribute to a more robust immune response, which may provide 
a greater level of protection. Preservation of these vaccine components is therefore, considered 
advantageous, particularly for veterinary vaccines, which favour highly immunogenic, single-dose 
vaccines.  
6.1.3 Simplified production and purification of modular capsomeres  
Chapter 4 demonstrated that soluble aggregates, E. coli contaminants and endotoxins present in the 
vaccine formulation do not alter the efficacy of the vaccine after two doses. Instead, these 
contaminants contribute to robust immune responses. This result also suggests the potential of crudely 
purified modular capsomeres as a poultry vaccine candidate. Motivated by this finding, this study 
aimed to simplify the production process of CaptHA1 by employing molecular and bioprocess 
engineering approaches. Non-tagged CaptHA1 constructs, denoted CaptHA1 and mCap, were 
generated. Capsomeres were expressed in E. coli and purified by selective precipitation using sodium 
sulfate (Na2SO4) and polyethylene glycol (PEG) 6000.  
CaptHA1 contains five copies of VP1dC-tHA. The mCap was generated by adopting a dual 
expression strategy to titrate the content of tHA1 presented in the capsomere to reduce a steric effect 
in the capsomere. The high expression and solubility levels of CaptHA1 and mCap were observed 
from the expression in E. coli SHuffle T7 Express cells and Rosetta 2 (DE3) cells, respectively. 
However, CaptHA1 provided a higher capsomere yield, while mCap formed mostly soluble 
aggregates following precipitation using 1 M Na2SO4. 
 113 
 
Optimisation of precipitation conditions was conducted to improve capsomere yield. CaptHA1 was 
precipitated using various concentrations of Na2SO4 and PEG 6000. Optimal yield of CaptHA1 was 
obtained when precipitated with 1 M Na2SO4 and 8% PEG 6000. However, Na2SO4-precipitated 
CaptHA1 contains more E. coli contaminants compared with PEG-precipitated CaptHA1. 
The HA1 antigen in precipitated CaptHA1 was specifically detected using anti-HA1 chicken antisera 
under both denatured and non-denatured conditions. Strong hemagglutination of precipitated 
CaptHA1 was observed with endpoint titre of 512 and 1024 for PEG- and Na2SO4- precipitated 
CaptHA1, respectively. This suggests that the presence of intact HA1 structures facilitates its binding 
of sialic acid on the surface of red blood cells. It also suggests that precipitation using either PEG or 
Na2SO4 does not destroy the structural integrity of CaptHA1. Additionally, these results reveal that 
precipitated CaptHA1 is as effective as chromatographically purified CaptHA1. 
The yield of Na2SO4- and PEG-precipitated CaptHA1 before the buffer exchange and endotoxin 
removal processes was approximately 36 mg.L-1 and 48 mg.L-1, respectively. However, the 
subsequent steps for buffer exchange and endotoxin removal may lead to decreases in final target 
protein recovery. 
Despite low purity levels, the yield of precipitated CaptHA1 was considerably higher than that of 
chromatographically purified CaptHA1, which was only 2.4 mg.L-1 following GST-affinity 
chromatography and 0.22 mg.L-1 with 91% purity following enzymatic release of GST and separation 
of CaptHA1 from GST tags and protein aggregates using SEC.  
This study demonstrated a simple chromatography-free process for producing CaptHA1, which is 
superior to the previously established chromatographic approach in terms of production speed. In 
addition, this simpler process eliminated complex chromatography steps, GST-affinity 
chromatography and subsequent GST removal in particular; thus, production costs are likely to be 
substantially reduced. A significant improvement was also achieved in the final yield, showing an 
increase of more than 30-fold.  
6.2 Future work 
This thesis introduced a novel capsomere vaccine platform that is suitable for modularising large 
heterologous antigenic modules and amendable to rapid industrial-scale vaccine manufacturing. This 
 114 
 
thesis contributes important findings to the design and process development of platform-based 
vaccine technology. These findings warrant further investigation in this field of study: 
(i) The modular capsomere (CaptHA1) formulated with an aluminium hydroxide 
(Alhydrogel) adjuvant induced strong immune responses when administered to 
chickens. Aluminium hydroxide was chosen to enable comparisons with previous 
studies; however, this adjuvant is not a standard adjuvant for animal vaccines. The 
investigation of CaptHA1 formulated with animal-relevant adjuvants such as oil 
emulsions [16] would identify the most suitable adjuvant for poultry vaccination. 
Further, the duration of the protective immune response should be monitored to fully 
evaluate effectiveness of vaccine candidates.  
(ii) The simplified bioprocess developed in this thesis allows the production of functional 
modular CaptHA1 at high yields without chromatography. To further increase 
capsomere yield, optimisation of protein expression conditions [17, 18] should be 
undertaken. Additionally, optimisation of selective precipitation conditions [5, 6, 19] 
or integration of filter-based technology such as membrane filtration [20, 21] may 
improve the final yield and purity of modular capsomeres. Future work should include 
in vivo immunogenicity and protective efficacy studies in chickens using vaccine 
candidates processed with newly developed methods.  
(iii) Poultry vaccination is a powerful tool to support viral eradication programmes, 
particularly when partnered with other control strategies. Vaccination programmes 
must allow differentiation between infected and vaccinated animals (DIVA). The 
DIVA strategy enables the detection of field exposure in vaccinated animals based on 
heterologous vaccination. The CaptHA1 contains only hemagglutinin (HA1), making 
it applicable to the DIVA concept. Further studies (field trials) are needed to evaluate 
the use of CaptHA1 as a feasible DIVA vaccine. Differentiation of CaptHA1-
vaccinated chickens from vaccinated and then infected chickens can be achieved 
through the detection of antibodies to other viral proteins such as nucleoprotein, matrix 
protein, NS1 or neuraminidase.  
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(iv) The HA1 antigenic module in CaptHA1 generated in this thesis was derived from the 
influenza A strain of either A/Puerto Rico/8/34 H1N1 (PR8 H1N1) or HPAI 
A/chicken/NSW/3122-1/2012 H7N7. PR8 H1N1 was used in this study to benchmark 
against previous studies, and HPAI H7N7 was used to allow viral challenge study in 
chickens. The evaluation of modular capsomere comprising HA1 from persistently 
circulating viruses among poultry populations, such as HPAI viruses subtype H5N1, 
H5N8 and H7N9, is crucial for the development of a poultry vaccine to control HPAI 
outbreaks. The adaptability of the capsomere vaccine platform to a variety of HA1 
subtypes is a warranted study to support the implementation of this platform as a 
strategy for AI preparedness. In addition, the VP1dC capsomere platform could be 
applicable when designing improved influenza vaccines for other species, including 
horses, pigs and humans. The need for an updated, rapidly produced and strain-
matched influenza vaccine is a significant hurdle in the control of influenza in all 
species, including humans. This capsomere platform might also be interesting when 
designing emergency vaccines for other diseases unrelated to avian influenza. 
6.3 Concluding thoughts 
Highly pathogenic avian influenza remains a global threat to animal and public health. Control 
measures such as biosecurity and stamping out are not always achievable for social, economic and 
ethical reasons. Vaccination provides a suitable means to control avian influenza outbreaks and 
prevent potential transmission to humans. The constraints of commercialised poultry influenza 
vaccines, which are produced mainly in eggs or cell cultures, underline the need for rapid vaccine 
manufacturing for the effective control of avian influenza. This thesis sought to develop a rapidly 
manufactured, low-cost poultry vaccine that is safe and efficacious. The newly-designed murine 
polyomavirus capsomere platform (VP1dC) was modularised with the large structure-based designed 
HA1 antigen (tHA1) from influenza A virus. The stable modular capsomere (CaptHA1) was 
successfully produced in E. coli without the need for protein refolding. This CaptHA1 induced 
protective immunity in chickens, verifying its potential as a poultry vaccine candidate. Further, the 
simplified process for producing CaptHA1 demonstrated the possibility for producing modular 
capsomeres at a scale, speed and cost that is unattainable using eggs or cell cultures. This microbial-
based modular capsomere platform for vaccine manufacturing would yield sufficient vaccines at an 
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affordable price for both developed and developing countries during avian influenza epidemics and 
pandemics. Importantly, this modular vaccine platform and production strategy is applicable to other 
vaccine designs for modularisation of large antigenic modules to generate vaccines that have not been 
possible using conventional methods. 
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